Therapeutic Approaches to Cancer-Associated Immune Suppression

  • Robert K. Oldham

Abstract

It is now well established that many cancer patients exhibit in vivo and in vitro evidence of immune suppression, which often correlates with tumor-cell burden, stage of disease, and prognosis. Cancer-associated immune suppression appears to be a direct result of the presence of disease, or follows treatment for it, rather than being an antecedent or predisposing condition. However, the precise role that nonspecific and/or specific antitumor immunity plays in the control of human cancer remains controversial. Indeed, there is some evidence that suggests that the development of certain antitumor immune responses may lead to augmented tumor cell growth rather than tumor regression [314,442,443].

Keywords

Chronic Lymphocytic Leukemia Natl Cancer Inst Transfer Factor Natural Killer Activity Thymic Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Addison I, Baggage J, Gandossini M, Souhami R. Assessment of host defense against infection during chemotherapy of Hodgkin’s disease. Cancer Chemother Pharmacol 1978; 1: 129–133.PubMedGoogle Scholar
  2. 2.
    Adler A, Stein JA, Ben-Efraim S. Immunocompetence, immunosuppression, and human breast cancer, II. Further evidence of initial immune impairment by integrated assessment effect of nodal involvement (N) and of primary tumor size (T). Cancer 1980; 45: 2061–2073.PubMedGoogle Scholar
  3. 3.
    Adler A, Stein JA, Ben-Efraim S. Immunocompetence, immunosuppression, and human breast cancer. III. Prognostic significance of initial level of immunocompetence in early and advanced disease. Cancer 1980; 45: 2074–2083.PubMedGoogle Scholar
  4. 4.
    Ahmed K, Turk JL. Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro. Cancer Immunol Immunother 1989; 28: 87–92.PubMedGoogle Scholar
  5. 5.
    Alberola V, Gonzalez-Molina A, Trenor A, et al. Mechanism of suppression of the depressed lymphocyte response in lung cancer patients.Allergol Immunopathol (Madr) 1985; 13:213–219.Google Scholar
  6. 6.
    Albin RJ, Gordon MJ, Soane WA. Levels of immunoglobulins in the serum of patients with carcinoma of the prostate. Neoplasma 1972; 19: 57–60.Google Scholar
  7. 7.
    Alexopoulos LG, Wiltshaw E. Immunological monitoring during chemotherapy for advanced Hodgkin’s disease. Cancer 1978; 42: 2631–2640.PubMedGoogle Scholar
  8. 8.
    Alsabti EA. In vivo and in vitro assays of incompetence in bronchogenic carcinoma. Oncology 1979; 36: 171–175.PubMedGoogle Scholar
  9. 9.
    Amery WK, Butterworth BS. The dosage regimen of levamisole in cancer: Is it related to efficacy and safety? Int JImmunopharmacol 1983; 5: 1–9.Google Scholar
  10. 10.
    Amery WK, Cosemans J, Gooszen HC, et al. Four-year results from double-blind study of adjuvant levamisole treatment in resectable lung cancer. In: Terry WDRosenberg SA, eds. Immunotherapy of human cancer. New York: Elsevier/North-Holland, 1982: 123–133.Google Scholar
  11. 11.
    Amlot PL, Anger A. Binding of phytohaemagglutinin to serum substances and inhibition of lymphocyte transformation in Hodgkin’s disease. Clin Exp Immunol 1976; 26: 520–527.PubMedGoogle Scholar
  12. 12.
    Anderson TC, Jones SE, Sochnlen BJ, et al. Immunocompetence and malignant lymphomas: Immunologic status before therapy.Cancer 1981; 48: 2702–2709.PubMedGoogle Scholar
  13. 13.
    Anderson TM, Ibayashi Y, Tokuda Y, et al. Natural killer activity of lymphocytes infiltrating human lung cancers following preoperative systemic recombinant interleukin- 2. Arch Surg 1987; 122: 12; 1446–1450.PubMedGoogle Scholar
  14. 14.
    Anderson TM, Ibayashi Y, Holmes EC, Golub SH. Modification of natural killer activity of lymphocytes infiltrating human lung cancers. Cancer Immunol Immunother 1987; 25:65–68,PubMedGoogle Scholar
  15. 15.
    Anthony HM, Templeman GH, Madsen KE, Mason MK. The prognostic significance of DHS skin tests in patients with carcinoma of bronchus. Cancer 1974: 1901-1906.Google Scholar
  16. 16.
    Anthony HM. Yorkshire trial of adjuvant therapy with levamisole in surgically treated lung cancer. In: Terry WDRosenberg SA, eds. Immunotherapy of human cancer. New York: Elsevier/North-Holland, 1982: 135–440.Google Scholar
  17. 17.
    Aparicio-Pages NM, Verspaget HW, Pena SA, Lamers CB. Impaired local natural killer-cell activity in human colorectal carcinomas. Cancer Immunol Immunother 1989; 28:4,301–304.PubMedGoogle Scholar
  18. 18.
    Aparicio-Pages NM, Verspaget HW, Pena SA, Lamers CBHW. Impaired local natural killer cell activity in human colorectal carcinomas. Cancer Immunol Immunother 1989; 28:301–304.PubMedGoogle Scholar
  19. 19.
    Aranha GV, McKhann CF, Simmons RL, Grage TB. Recall skin test antigens and the prognosis of stage I melanoma. J Surg Oncol 1976; 11: 13–16.Google Scholar
  20. 20.
    Arinaga S, Akiyoshi T, Tsuji H. Augmentation of the generation cell mediated cytotoxicity after a single dose of adriamycin in cancer patients. Cancer Res 1986; 46: 4213–4216.PubMedGoogle Scholar
  21. 21.
    Arinaga S, Akiyoshi T, Tsuji H. Augmentation of the cellmediated cytotoxic response induced in mixed cell culture by adriamycin. Jpn J Cancer Res 1985; 76: 414–419.PubMedGoogle Scholar
  22. 22.
    Armstrong D, Chmel M. Infectious complications of Hodgkin’s disease. In: Lacher MJ, ed. Hodgkin’s disease. New York: Wiley, 1976: 267–290.Google Scholar
  23. 23.
    Arnaud JP, Buyse M, Nordlinger B, et al. Adjuvant therapy of poor prognosis colon cancer with levamisole: Results of an EORTC double-blind randomized clinical trial. Br J Surg 1989; 76:284–289.PubMedGoogle Scholar
  24. 24.
    Ascher MS, Schneider WJ, Valentine FT, Lawrence HS. In vitro properties of leukocyte dialy sates containing transfer factor. Proc Natl Acad Sci USA 1974; 74: 1178–1182.Google Scholar
  25. 25.
    Ashorn RG, Vandenbard AA, Acott KM, Krohn KJ. Dialysable leukocyte extracts (transfer factor) augment non-specifically keyhole limpet haemocyanin and horseshoe crab haemocyanin skin reactivity in immunized human recipients. Scand J Immunol 1976; 23: 161–167.Google Scholar
  26. 26.
    Aymard JP, Janot C, Thibaut G, et al. Levamisole in chronic lymphocytic leukaemia: A prospective study of 15 patients. Acta Haematol (Basel) 1984; 71:316–321.Google Scholar
  27. 27.
    Balaram P, Remani P, Padmanabhan TK, Vasudevan DM. Role of levamisole immunotherapy as an adjuvant to radiotherapy in oral cancer: Immune responses. Neoplasma 1988; 35: 6; 617–625.PubMedGoogle Scholar
  28. 28.
    Balaram P, Padmanabhan TK, Vasudevan DM. Role of levamisole immunotherapy as an adjuvant to radiotherapy in oral cancer. II. Lymphocyte subpopulations. Neoplasma 1988; 35: 2; 235–242.PubMedGoogle Scholar
  29. 29.
    Balch CM, Doughtery PA, Cloud GA, Tilden AB. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery 1984; 95: 71–77.PubMedGoogle Scholar
  30. 30.
    Balch CM, Tilden AB, Dougherty PA, Cloud GA. Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg 1983; 198: 192–199.PubMedGoogle Scholar
  31. 31.
    Balch CM, Dougherty PA, Tilden AB. Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients. Ann Surg 1982; 196: 645–650.PubMedGoogle Scholar
  32. 32.
    Balm FA, Drexhage HA, vonBlomberg M, et al. Mononuclear phagocytic function in head and neck cancer. Cancer 1984; 54: 1010–1015.PubMedGoogle Scholar
  33. 33.
    Bancewicz J, Caiman K, MacPherson SG, et al. Adjuvant chemotherapy and immunotherapy for colorectal cancer; preliminary communication. JR Soc Med 1980; 73: 197–199.Google Scholar
  34. 34.
    Baral E, Blomgren H, Petrini B, Wasserman J. Blood lymphocytes in breast cancer patients following radiotherapy and surgery. Int J Radiat Oncol Biol Phys 1977; 2: 289–295.PubMedGoogle Scholar
  35. 35.
    Baral E, Blomgren H, Petrini B, et al. Prognostic relevance of immunologic variables in breast carcinoma. Acta Radiol Ther Phys Biol 1977; 16: 417–426.PubMedGoogle Scholar
  36. 36.
    Baseler MW, Maxim PE, Veltri RW. Circulating IgA immune complexes in head and neck cancer, nasopharyngeal carcinoma, lung cancer, and colon cancer. Cancer 1987; 59: 1727–1731.PubMedGoogle Scholar
  37. 37.
    Baskies AM, Chretien PB, Weiss JF, et al. Serum glycoproteins in cancer patients: First report of correlations with in vitro and in vivo parameters and cellular immunity. Cancer 1980; 45: 3050–3060.PubMedGoogle Scholar
  38. 38.
    Bast RC, Reinherz EL, Maven C, et al. Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. Clin Immunol Immunopathol 1983; 28: 101–114.PubMedGoogle Scholar
  39. 39.
    Baumann MA, Milson TJ, Patrick CW, et al. Correlation of circulating natural killer cell count with prognosis in large cell lymphoma. Cancer 1986; 57: 2309–2312.PubMedGoogle Scholar
  40. 40.
    Bean MA, Schelhammer PS, Her HW, et al. Immunocompetence of patients with transitional cell carcinoma as measured by DNCB skin tests and in vitro lymphocyte function. Natl Cancer Inst Monogr 1978; 49: 111–114.PubMedGoogle Scholar
  41. 41.
    Bedikian AY, Patt YZ, Murphy WK, et al. Prospective evaluation of thymosin fraction V immunotherapy in patients with non-small cell lung cancer receiving vindesine, doxorubicin, and cisplatin (VAP) chemotherapy. Am J Clin Oncol 1984; 7: 399–404.PubMedGoogle Scholar
  42. 42.
    Benkovic B, Burek B, Jaksic B, Vitale B. Modulation of chronic lymphocytic leukemia (CLL) lymphocyte phenotypes by in vitro incubation with alpha-1 thymosin. Blood Cells 1987; 12:2; 441–455.PubMedGoogle Scholar
  43. 43.
    Bennett A, Berstock A, Harris M, et al. Prostaglandins and their relationship to malignant and benign breast tumors. In: Sammuelsson BRamuell PWPaoletti R, eds. Advances in prostaglandin and thromboxane research vol 6. New York: Raven Press, 1980: 595–599.Google Scholar
  44. 44.
    Berd D, Macguire HC Jr, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986; 46: 2512–2511.Google Scholar
  45. 45.
    Berd D, Mastrangelo MJ, Enstron PF, et al. Augmentation of the human immune response by cyclophosphamide. Cancer Res 1982; 42: 4862–4866.PubMedGoogle Scholar
  46. 46.
    Berd D, Wilson EJ, Bellet RE, Mastrangelo MJ. Effect of 1-(2-chlorethyl)-3-(4-methyl-cyclohexyl) -1 - nitrosourea adjuvant therapy on the immune response of patients with malignant melanoma. Cancer Res 1979; 39:4472–4476.PubMedGoogle Scholar
  47. 47.
    Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: Reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res 1987; 47: 3317–3321.PubMedGoogle Scholar
  48. 48.
    Berd D, Maguire HC, Mastrangelo MJ. Impairment of concanavalin A-inducible suppressor activity following administration to patients with advanced cancer. Cancer Res 1984; 44: 1275–1280.PubMedGoogle Scholar
  49. 49.
    Berenbaum MC, Fluck PA, Hurst NP. Depression of lymphocyte responses after surgical trauma. Br J Exp Pathol 1973; 54: 597–607.PubMedGoogle Scholar
  50. 50.
    Berenyl E, Kavai M, Szabolcsi M, Szegedi G. Levamisole in the treatment of Hodgkin’s disease. Acta Med Acad Sci Hung 1979; 36: 177–185.Google Scholar
  51. 51.
    Bergman S, Borgstrom S, Tarnik A. Lymphocyte response to phytohaemagglutinin following cholecystectomy. Acta Pathol Microbiol Scand 1969; 75: 363–366.PubMedGoogle Scholar
  52. .
    Bergmann L, Mitrou PS, Demmer-Dieckmann M, et al. Impaired T- and B-cell functions in patients with Hodgkin’s disease. Cancer Immunol Immunother 1987; 25:59–64.PubMedGoogle Scholar
  53. 53.
    Berkarda B, Bouffard-Eyaboglu H, Derman U. The effect of coumarin derivatives on the immunological system of man. Agents Actions 1983; 13: 50–52.PubMedGoogle Scholar
  54. 54.
    Berlinger NT. Deficient immunity in head and neck cancer due to excessive monocyte production of prostaglandins. Laryngoscope 1984; 94(11 Ptl): 1407–1410.PubMedGoogle Scholar
  55. 55.
    Bernengo MG, Fra P, Lisa F, Meregilli M, Zina G. Thymostimulin therapy in melanoma patients: Correlation of immunologic effects with clinical course. Clin Immunol Immunopathol 1983; 28: 311–324.PubMedGoogle Scholar
  56. 56.
    Bernengo MG, Lisa F, Meregalli M, et al. The prognostic value of T-lymphocyte levels in malignant melanoma. A five year follow-up. Cancer 1983; 52: 1841–1898.PubMedGoogle Scholar
  57. 57.
    Bernengo MG, Lisa F, Meregalli M, Doveil GC. Changes inT- and B-lymphocyte subpopulations before, during and after chemotherapy for malignant melanoma. Int J Tissue React 1984; 6: 505–511.PubMedGoogle Scholar
  58. 58.
    Bicker U. Immunomodulation by 2-cyanaziridine derivatives. In: Serrou BRosenfeld CDaniels JCSaunder JP, eds. Current concepts in human immunology and cancer immunomodulation. Amsterdam: Elsevier Biomedical, 1982:521–534.Google Scholar
  59. 59.
    Bier J, Nicklisch U, Platz H. The doubtful relevance of nonspecific immune reactivity in patients with squamouscell carcinoma of the head and neck region. Cancer 1983; 52: 1165–1172.PubMedGoogle Scholar
  60. 60.
    Bjorkholm M, Wedelin C, Holm G, et al. Lymphocytotoxic serum factors and lymphocyte functions in untreated Hodgkin’s disease. Cancer 1982; 50: 2044–2048.PubMedGoogle Scholar
  61. 61.
    Bjorkholm M, Holm G, Mellstedt H. Persisting lymphocyte deficiencies during remission in Hodgkin’s disease. Clin Exp Immunol 1977; 28: 389–393.PubMedGoogle Scholar
  62. 62.
    Bjorkholm M, Holm G, Mellstedt H. Immunologic profile of patients with cured Hodgkin’s disease. Scand J Hematol 1977; 18:361–368.Google Scholar
  63. 63.
    Bjorkholm M, Holm G, Mellsted H, Johansson B. Immunodeficiency and prognosis in Hodgkin’s disease. Acta Med Scand 1975; 198: 275–279.PubMedGoogle Scholar
  64. 64.
    Block JB, Haynes HA, Thompson WL, Neiman PE. Delayed hypersensitivity in chronic lymphocytic leukemia. J Natl Cancer Inst 1969; 42: 973–980.PubMedGoogle Scholar
  65. 65.
    Blomgren H, Edsmyr F, Esposti PL, et al. Influence of bestatin, a new immunomodifier, on human lymphoid cells. In: Serrou BRosenfeld CDaniels JCSaunders JP, eds. Current concepts in human immunology and cancer immunomodulation. Amsterdam: Elsevier Biomedical, 1982:593–610.Google Scholar
  66. 66.
    Blomgren H, Edsmyr F, Esposti PL, Naslund I. Immunological and haematological monitoring in bladder cancer patients receiving adjuvant bestatin treatment following radiation therapy. A prospective randomized trial. Biomed Pharmacother 1984; 38: 143–149.PubMedGoogle Scholar
  67. 67.
    Blomgren SE, Wolberg WH, Kisken WA. Effect of fluoropyrimidines on delayed cutaneous hypersensitivity. Cancer Res 1965; 25: 977–979.PubMedGoogle Scholar
  68. 68.
    Blomgren H, Wasserman J, Rotstein S, et al. Possible role of prostaglandin-producing monocytes in the depression of mitogenic response of blood lymphocytes following radiation therapy. Radiother Oncol 1984; 1: 255–261.PubMedGoogle Scholar
  69. 69.
    Blomgren H, Baral E, Edsmyr F, et al. Natural killer activity in peripheral blood lymphocyte populations following local radiation therapy. Acta Radiol Oncol 1980; 2: 139–143.Google Scholar
  70. 70.
    Blomgren H, Wasserman J, Littbrand B. Blood lymphocytes after radiation therapy of carcinoma of prostate and urinary bladder. Acta Radiol Ther Phys Biol 1974; 13: 357–367.PubMedGoogle Scholar
  71. 71.
    Blomgren H, Naslund I, Esposti PL, et al. Adjuvant bestatin immunotherapy in patients with transitional cell carcinoma of the bladder. Clinical results of a randomized trial. Cancer Immunol Immunother 1987; 25: 1; 46.Google Scholar
  72. 72.
    Blomgren H, Strender LE, Petrini B, Wasserman J. Changes of the spontaneous cytotoxicity of the blood lymphocyte population following local radiation therapy for breast cancer. Eur J Cancer Clin Oncol 1982; 18: 637–643.PubMedGoogle Scholar
  73. 73.
    Blomgren H, Wasserman J, Baral E, Petrini B. Evidence for the appearance of non-specific suppressor cells in the blood after local irradiation therapy. Int J Radiol Oncol Biol Phys 1978; 4: 249–253.Google Scholar
  74. 74.
    Blomgren H, Strender LE, Edsmyr F. Bestatin treatment and the peripheral lymphocyte population in cancer patients. Recent Results Cancer Res 1980; 75: 133–138.PubMedGoogle Scholar
  75. 75.
    Blomgren H, Edsmyr F, vonStedingk L-V Wasserman J. Bestatin treatment enhances the recovery of radiationinduced impairments of the immunological reactivity of the blood lymphocyte population in bladder and cancer patients. Biomed Pharmacother 1986; 40: 50–54.PubMedGoogle Scholar
  76. 76.
    Bobrove AM, Fuks Z, Strober S. Quantitation of T- and Blymphocytes and cellular immune function in Hodgkin’s disease. Cancer 1975; 36: 169–179.PubMedGoogle Scholar
  77. 77.
    Bockman RS. Prostaglandins in cancer: a review. Cancer Invest 1983; 1:485–493.PubMedGoogle Scholar
  78. 78.
    Boetcher DA, Leonard EJ. Abnormal monocyte chemotactic response in cancer patients. J Natl Cancer Inst 1974;52:1091–1098.PubMedGoogle Scholar
  79. 79.
    Bollag W, Matta A. From vitamin A to retinoids in experimental and clinical oncology: achievements, failures, and outlook. Ann NY Acad Sci 1981; 359: 9–23.PubMedGoogle Scholar
  80. 80.
    Bolton PM, Teasdale C, Mander AM, et al. Immune competence in breast cancer: relationships of pretreatment immunologic tests to diagnosis and tumor stage. Cancer Immunol Immunother 1976; 1: 251–258.Google Scholar
  81. 81.
    Bolton PM, Mander AM, Davidson JM, et al. Cellular immunity in cancer: comparison of delayed hypersensitivity skin tests in three common cancers. Br J Med 1975; 3(5974) 18–20.Google Scholar
  82. 82.
    Bone G, Appleton DR, Venebles CW. The prognostic value of the cutaneous delayed hypersensitivity response to 2,4-dinitrochlorobenzene in gastrointestinal cancer. Br J Cancer 1974; 29:403–406.PubMedGoogle Scholar
  83. 83.
    Borden EC, Davis TE, Crowley JJ, et al. Interim analysis of trial of levamisole and 5-fluorouracil in metastatic colorectal carcinoma. In: Terry WDRosenberg SA, eds. Immunotherapy of human cancer. New York: Elsevier/ North-Holland, 1982: 231–235.Google Scholar
  84. 84.
    Bosworth JL, Ghossein NA, Brooks TL. Delayed hypersensitivity in patients treated by curative radiotherapy. Its relation to tumor response and short-term survival. Cancer 1975; 36: 353–358.PubMedGoogle Scholar
  85. 85.
    Braun DP, Nisius S, Hollinshead A, Harris JE. Serial immune testing in surgically resected lung cancer patients. Cancer Immunol Immunother 1983; 15: 114–120.PubMedGoogle Scholar
  86. 86.
    Braun DP, Harris JE, Rugenstein M. Relationships of arachidonic acid metabolism to indomethacin-sensitive immunoregulatory function and lymphocyte PGE sensitivity in peripheral blood mononuclear cells of disseminated solid-tumor cancer patients. JImmunopharmacol 1984; 6: 227–236.Google Scholar
  87. 87.
    Braun DP, Harris JE. Effects of combination chemotherapy on immunoregulatory cells in peripheral blood of solid-tumor cancer patients: Correlation with rebound randomized trial. Cancer Immunol Immunother 1987; 25: 1; 46.Google Scholar
  88. 88.
    Braun DP, Harris JE. Modifications of the effects of cytotoxic chemotherapy on the immune responses of cancer patients with a non-steroidal, anti-inflammatory drug, piroxicam. (Abstr.) Proc Am Soc Clin Oncol 1985; 4:223.Google Scholar
  89. 89.
    Brenner BG, Friedman G, Margolese RG. The relationship of clinical status and therapeutic modality to natural killer cell activity in human breast cancer. Cancer 1985; 56: 1543–1548.PubMedGoogle Scholar
  90. 90.
    Brooks WH, Caldwell HD, Mortara RH. Immune responses in patients with gliomas. Surg Neurol 1974; 2: 419–423.PubMedGoogle Scholar
  91. 91.
    Brosman S, Elhilali M, Vescura C, Fahey J. Immune response in bladder cancer patients. J Urol 1979; 121: 162–169.PubMedGoogle Scholar
  92. 92.
    Brosman S, Hausman M, Shacks SJ. Studies on the immune status of patients with renal adenocarcinoma. J Urol 1975;114:375–380.PubMedGoogle Scholar
  93. 93.
    Browder JP, Cretien PB. Immune reactivity in head and neck squamous carcinoma and relevance to the design of immunotherapy trials. Sem Oncol 1977; 4: 4; 431–439.Google Scholar
  94. 94.
    Brown AE, Badger AM, Poste G. The effects of cimetidine on immune cell function and host response to tumors. In: Serrou BRosenfeld CDaniels JCSanders JP, eds. Current concepts of human immunology and cancer immunomodulation. Amsterdam: Elsevier Biomedical, 1982:513–519.Google Scholar
  95. 95.
    Bruckner HW, Mokyr MB, Mitchell MS. Effect of imidazole-4-carboxamide-5 -(3, 3 -dimethyl-1 -triazeno) on immunity in patients with malignant melanoma. Cancer Res 1974; 34: 181–183.PubMedGoogle Scholar
  96. 96.
    Bukowski RM, Deodhar S, Hewlett JS, Greenstreet R. Randomized controlled trial of transfer factor in stage II malignant melanoma. Cancer 1983; 51: 269–272.PubMedGoogle Scholar
  97. 97.
    Buroker TR, Moertel CG, Fleming TR, et al. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol 1985; 3: 1624–1631.PubMedGoogle Scholar
  98. 98.
    Burtin C, Noirot C, Scheinmann P, et al. Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (rantidine or cimetidine). Eur J Cancer Clin Oncol 1988; 24:2,161–167.PubMedGoogle Scholar
  99. 99.
    Busutti L, Blotta A, Mastrorilli M, et al. Transfer factor adjuvant therapy in non-small-cell lung carcinoma (NSCLC) after surgery and radiotherapy. J Exp Pathol 1987;3:4, 565–568.PubMedGoogle Scholar
  100. 100.
    Butterworth C, Oon CJ, Westbury G, Hobbs JR. Tlymphocyte response in patients with malignant melanoma. Eur J Cancer 1977; 10: 639–646.Google Scholar
  101. 101.
    Cairo MS, Mallett C, Vande Ven C, et al. Impaired in vitro polymorphonuclear function secondary to the chemotherapeutic effects of vincristine, adriamycin, cyclophosphamide, and actinomycin D.J Clin Oncol 1986;5:798–804.Google Scholar
  102. 102.
    Cameron DJ. A comparison of the cytotoxic potential in polymorphonuclear leukocytes obtained from normal donors and cancer patients. Clin Immunol Immunopathol 1983;28:115–124.PubMedGoogle Scholar
  103. 103.
    Cameron DJ, O’Brien P, Majeski JA. Effects of in vivo treatment with ibuprofen on macrophage function in breast and colon cancer patients. J Clin Lab Immunol 1986; 20: 1,23–28.PubMedGoogle Scholar
  104. 104.
    Cannon GB, Dean JH, Herberman RB, et al. Association of depressed postoperative lymphoproliferative responses to alloantigens with poor prognosis in patients with stage I lung cancer. Int J Cancer 1980; 25: 9–17.PubMedGoogle Scholar
  105. 105.
    Carmignani G, Belgrano E, Puppo P, Cornaglia P. Tlymphocyte- inhibiting factors in renal cancer: Evaluation of differences between arterial and renal venous blood levels of E-rosette-forming cells. J Urol 1978; 120: 673–675.PubMedGoogle Scholar
  106. 106.
    Carpenter JT Jr, Smalley RV, Raney M, et al. Ineffectiveness of levamisole in prolonging remission or survival of women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: A Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986; 70:9; 1073–1079.PubMedGoogle Scholar
  107. 107.
    Case DC, Hansen JA, Corrales E, et al. Depressed in vitro lymphocyte responses to PHA in patients with Hodgkin’s disease in continuous long remissions. Blood 1977; 49: 771–778.PubMedGoogle Scholar
  108. 108.
    Catalona WJ, Ratliff TL, McCool RE. Discordance among cell-mediated cytolytic mechanisms in cancerous patients: importance of the assay system. J Immunol 1979; 122: 1009–1014.PubMedGoogle Scholar
  109. 109.
    Catalona WJ, Tarpley JL, Potvin C, Chretien PB. Host immunocompetence in genitourinary cancer: Relationship to tumor stage and prognosis. Natl Cancer Inst Monogr 1978; 49: 105–110.PubMedGoogle Scholar
  110. 110.
    Catalona WJ, Chretien PB. Abnormalities of quantitative dinitrochlorobenzine sensitization in cancer patients: Correlation with tumor stage and histology. Cancer 1973; 31:353–356.PubMedGoogle Scholar
  111. 111.
    Catalona WJ, Sample WF, Chretien PB. Lymphocyte reactivity in cancer patients: Correlation with tumor histology and clinical stage. Cancer 1973; 31: 65–71.PubMedGoogle Scholar
  112. 112.
    Catalona WJ, Tarpley JL, Potvin C, Chretien PB. Correlations among cutaneous reactivity to DNCB, PHAinduced lymphocyte blastogenesis and peripheral blood E-rosettes. Clin Exp Immunol 1975; 19: 327–332.PubMedGoogle Scholar
  113. 113.
    Catalona WJ, Ratliff TL, McCool R. Concanavalin-Aactivated suppressor cell activity in peripheral blood lymphocytes of urologic cancer patients. J Natl Cancer Inst 1980; 65:553–557.PubMedGoogle Scholar
  114. 114.
    Caulfield MJ, Luce KJ, Proffitt MR, Cevy J. Induction of idiotype-specific suppressor T-cells with antigen/ antibody complexes. J Ex Med 1983; 157: 1713–1725.Google Scholar
  115. 115.
    Cervical Cancer Immunotherapy Study Group. Immunotherapy using the streptococcal preparation OK- 432 for the treatment of uterine cervical cancer. Cancer 1987;60:2394–2402.Google Scholar
  116. 116.
    Chahinian AP, Goldberg J, Holland JF, et al. Chemotherapy vs. Chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer. Cancer Treat Rep 1982; 66: 1291–1297.PubMedGoogle Scholar
  117. 117.
    Chang TC, Statzman L, Sokal JE. Correlation of delayed hypersensitivity responses with chemotherapeutic results in advanced Hodgkin’s disease. Cancer 1975; 36: 950–955.PubMedGoogle Scholar
  118. 118.
    Cheema AR, Hersh EM. Patient survival after chemotherapy and its relationship to in vitro lymphocyte blastogenesis. Cancer 1971; 28: 851–855.PubMedGoogle Scholar
  119. 119.
    Chihara G, Hamuro J, Maeda YY, et al. Antitumor and metastasis-inhibitory activities of lentinan as an immuno modulator: An overview. Cancer Detect Prev Suppl 1987; 1:423–443.PubMedGoogle Scholar
  120. 120.
    Chirhara G. The antitumor polysaccharide lentinan: an overview. In: Aoki T, Urushizaki I, and Tsubara E, eds. Manipulation of host defense mechanisms. Excerpta Medica 1981: 1-16.Google Scholar
  121. 121.
    Chirigos MA, Mastrangelo MJ. Immunorestoration by chemicals. In: Milhich E, ed. Immunological approaches to cancer therapeutics. New York: Wiley, 1982: 191–239.Google Scholar
  122. 122.
    Chisesi T, Capnist G, Rancan L, et al. The effect of thymic substances on T-circulating cells of patients treated for Hodgkin’s disease. J Biol Regul Homeost Agents 1988; 2: 4,193–198.PubMedGoogle Scholar
  123. 123.
    Chlebowski RT, Nystrom S, Reynolds R, et al. Long-term survival following levamisole or placebo adjuvant treatment of colorectal cancer: a Western Cancer Study Group trial. Oncology 1988; 45: 3,141–143.PubMedGoogle Scholar
  124. 124.
    Clemens LE, Siiteri PK, Stities DP Mechanism of immunosuppression of progesterone of natural lymphocyte activation during pregnancy. J Immunol 1979; 122: 5; 1978–1985.PubMedGoogle Scholar
  125. 125.
    Cochran AJ, Mackie RM, Grant RM, et al. An examination of the immunology of cancer patients. Int J Cancer 1976; 18:298–309.PubMedGoogle Scholar
  126. 126.
    Cohen MH, Chretien PB, Johnston-Early A, et al. Thymosin fraction V prolongs survival of intensively treated small-cell lung cancer patients. In: Terry WDRosenberg SA, eds. Immunotherapy of human cancer. New York: Elsevier/North-Holland, 1982: 141–145.Google Scholar
  127. 127.
    Cohen JHD, Danel L, Cordier G, et al. Sex steroid receptors in peripheral T-cell: Absence of androgen receptors to OKT8-positive cells. J Immunol 1983; 131: 2767–2771.PubMedGoogle Scholar
  128. 128.
    Cohen MH, Chretien PB, Indo DC, et al. Thymosin fraction V and intensive combination chemotherapy prolonging the survival of patients with small-cell lung cancer. JAMA 1979; 241: 1813–1815.PubMedGoogle Scholar
  129. 129.
    Colozza M, Tonato M, Belsanti V, et al. 5-Fluorouracil and isoprinosine in the treatment of advanced colorectal cancer: A limited phase I, II evaluation. Cancer 1988; 62: 1049–1052.PubMedGoogle Scholar
  130. 130.
    Cone L, Uhr JW. Immunological deficiency disorders associated with chronic lymphocyte leukemia and multiple myeloma. J Clin Invest 1964; 43: 2241–2249.PubMedGoogle Scholar
  131. 131.
    Consolini R, Cei B, Cini P, et al. Circulating thymic hormone activity in young cancer patients. Clin Exp Immunol 1986; 66: 1;173–180.PubMedGoogle Scholar
  132. 132.
    Corder MP, Young RC, Brown RS, DeVita VT. Phytohemagglutinin- induced lymphocyte transformation: The relationship to prognosis of Hodgkin’s disease. Blood 1972;39:595–601.PubMedGoogle Scholar
  133. 133.
    Costanzi JJ, Fletcher WS, Balcerzak SP, et al. Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group Study. Cancer 1984; 53: 833–836.PubMedGoogle Scholar
  134. 134.
    Cozzolino F, Torcia M, Carossino AM, et al. Characterization of cells from invaded lymph nodes in patients with solid tumors. J Exp Med 1987; 166: 303–318.PubMedGoogle Scholar
  135. 135.
    Cullen BF, VanBelle G. Lymphocyte transformation and changes in leukocyte count. Effect of anesthesia and operation. Anesthesiology 1975; 43: 563–569.Google Scholar
  136. 136.
    Cunningham-Rundles S, Filippa A, Braun DW, et al. Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer in women. J Natl Cancer Inst 1981; 67: 585–590.PubMedGoogle Scholar
  137. 137.
    Dagan S, Tzehoval E, Fridkin M, Feldman M. Tuftsin and tuftsin conjugates potentiate immunogenic processes: effects and possible mechanisms. J Biol Response Mod 1987; 6: 6,625–636.PubMedGoogle Scholar
  138. 138.
    Dalbow MH, Concannon JP, Eng CP, et al. Lymphocyte mitogen stimulation studies for patients with lung cancer: evaluation of prognostic significance of preirradiation therapy studies. J Lab Clin Med 1977; 90: 295–302.PubMedGoogle Scholar
  139. 139.
    Danel L, Sonweine G, Monier JC, Saez S. Specific estrogen binding sites in human lymphoid cells and thymic cells. J Steroid Biochem 1983; 18: 5; 559–563.PubMedGoogle Scholar
  140. 140.
    Danish Breast Cancer Cooperative Group. Increased breast cancer recurrence rate after adjuvant therapy with levamisole. Lancet 1980; 2: 824–827.Google Scholar
  141. 141.
    Das SN, Khanna NN, Khanna S.A multiparametric observation of immune competence in breast cancer and its correlation with tumor load and prognosis. Ann Acad Med Singapore 1985; 14: 374–381.PubMedGoogle Scholar
  142. 142.
    Davis S, Mietlowski W, Rohweder JJ, et al. Levamisole as an adjuvant to chemotherapy in extensive bronchogenic carcinoma. A Veterans Administration Lung Cancer Group study. Cancer 1982; 50: 646–651.Google Scholar
  143. 143.
    Dawson DE, Everts EC, Vetto RM, Burger DR. Assessment of immunocompetent cells in patients with head and neck squamous-cell carcinoma. Ann Otol Rhinol Laryngol 1985; 94: 342–345.PubMedGoogle Scholar
  144. 144.
    DeBoer KP, Braun DP, Harris JE. Natural cytotoxicity and antibody-dependent cytotoxicity in solid-tumor cancer patients: Regulation by adherent cells. Clin Immunol Immunopathol 1982; 23: 133–144.Google Scholar
  145. 145.
    DelGiacco GS, Cengiarotti L, Mantovani G, et al. Advanced lung cancer treated with combination chemotherapy with or without thymostimulin. In: Byrom NAHobbs JR, eds. Thymic factor therapy Serono Symposium Publications: New YorkRaven Press, 1982: 321–328.Google Scholar
  146. 146.
    Dellon AL, Potvin C, Chretien PB. Thymus-dependent lymphocyte levels during radiation therapy for bronchogenic and esophageal carcinoma: correlations with clinical course in responders and nonresponders. Am J RoentgenolRadiat TherNuclMed 1975; 123: 500–511.Google Scholar
  147. 147.
    Dellon AL, Potvin C, Chretien PB. Thymus-dependent lymphocyte levels in bronchogenic carcinoma: correlations with histology, clinical stage, and clinical course after surgical treatment. Cancer 1975; 35: 687–694.PubMedGoogle Scholar
  148. 148.
    Dillman RO, Beauregard JC, Zavanelli MI, et al. In vivo immune restoration in advanced cancer patients after administration of thymosin fraction V or thymosin alpha- 1. J Biol Response Mod 1983; 2: 139–147.PubMedGoogle Scholar
  149. 149.
    Dimitrov NV, Arnold D, Munson J, et al. Phase II study of thymosin fraction 5 in the treatment of metastatic renal cell carcinoma. Cancer Treat Rep 1985; 69: 137–138.PubMedGoogle Scholar
  150. 150.
    Dizon QS, Southam CM. Abnormal cellular response in skin abrasion in cancer patients. Cancer 1963; 16: 1288–1292.PubMedGoogle Scholar
  151. 151.
    Domellof L. Athlin L, Berghem L. Effects of long-term combination chemotherapy on the reticuloendothelial system. Cancer 1984; 53: 2073–2078.PubMedGoogle Scholar
  152. 152.
    Donoran AJ. Reticuloendothelial function in patients with cancer: initial observations. Am J Surg 1967; 111: 230–238.Google Scholar
  153. 153.
    Droller MJ, Schneider MU, Perlmann P.A possible role of prostaglandins in the inhibition of natural and antibodydependent cell-mediated cytotoxicity against tumor cells. Cell Immunol 1978; 39: 165–177.PubMedGoogle Scholar
  154. 154.
    Droller MJ, Perlmann P, Schneider MU. Enhancement of natural and antibody-dependent lymphocyte cytotoxicity by drugs which inhibit prostaglandin production by tumor target cells. Cell Immunol 1978; 39: 154–164.PubMedGoogle Scholar
  155. 155.
    Ducos J, Mingueres J, Colombio P, et al. Lymphocyte response to PHA in patients with lung cancer. Lancet 1970; 1: 111–112.Google Scholar
  156. 156.
    Dupont B, Ballon M, Hansen JA, et al. Effects of transfer factor therapy on mixed lymphocyte culture reactivity. Proc Natl Acad Sci USA 1974; 71: 867–871.PubMedGoogle Scholar
  157. 157.
    Edelman GM, Cunningham BA, Gall WE, et al. The covalent structure of and entire gamma G immunoglobulin molecule. Proc Natl Acad Sci USA 1969; 63: 78–85.PubMedGoogle Scholar
  158. 158.
    Ehrke MJ, Mihich E, Berd D, Mastrangelo MJ. Effects of anticancer drugs on the immune system in humans. Sem Oncol 1989; 16: 3; 230–253.Google Scholar
  159. 159.
    Eilber FR, Nizze HA, Morton DL. Sequential evaluation of general immune competence in cancer patients: Correlation with clinical course. Cancer 1975; 35: 660–665.PubMedGoogle Scholar
  160. 160.
    Eilber FR, Morton DL. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer 1970; 25: 362–367.PubMedGoogle Scholar
  161. 161.
    Eilber FR, Morton DL, Ketcham AS. Immunologic abnormalities in head and neck cancer. Am J Surg 1974; 128:534–538.PubMedGoogle Scholar
  162. 162.
    Eisenthal A, Monselise J, Zinger R, Adler A. The effect of cimetidine on PBL from healthy donors and melanoma patients: Augmentation of T-cell responses to TCGF mitogens and alloantigens and of TCGF production. Cancer Immunol Immunother 1986; 21:2; 141–147.PubMedGoogle Scholar
  163. 163.
    Eremin O, Ashby J, Franks D. Killer (K) cell activity in human normal lymph node, regional tumor lymph node, and inflammatory lymph node. Int Arch Allergy Appl Immunol 1977; 54: 210–220.PubMedGoogle Scholar
  164. 164.
    Eremin O, Ashby J, Stephens JP. Human natural cytotoxicity in the blood and lymphoid organs of healthy donors and patients with malignant disease. Int J Cancer 1978;21:35–41.PubMedGoogle Scholar
  165. 165.
    Ershler WB, Hacker MP, Burroughs BJ, et al. Cimetidine and the immune response. In vivo augmentation of nonspecific and specific immune response. Clin Immunol Immunopathol 1983; 26: 10–17.PubMedGoogle Scholar
  166. 166.
    Eskinazi DP, Perna J J, Mihail R. Mononuclear cell subsets in patients with oral cancer. Cancer 1987; 60: 376–381.PubMedGoogle Scholar
  167. 167.
    Estervez ME, Ballart IJ, Diez RA, et al. Normalization of monocyte candidacidal deficiency by cyclooxygenase inhibitors in Hodgkin’s disease. Cancer 1985; 55: 2114–2778.Google Scholar
  168. 168.
    Eura M, Maehara T, Tsutomo I, Ishikawa T. Suppressor cells in the effector phase of autologous cytotoxic reactions in cancer patients. Cancer Immunol Immunother 1988;27:147–153.PubMedGoogle Scholar
  169. 169.
    Ezdinli EZ, Simonson KL, Smith RA. Comparison of the effects of single vs. multiple agent chemotherapy on lymphocytes assayed by the rosette techniques. Cancer 1978;42:2234–2243.PubMedGoogle Scholar
  170. 170.
    Faguet GB, Davis HC. Survival in Hodgkin’s disease: The role of immunocompetence and other major risk factors. Blood 1982; 59: 938–945.PubMedGoogle Scholar
  171. 171.
    Fisher RI, Bostick-Bruton F. Depressed T-cell proliferative responses in Hodgkin’s disease: Role of monocytemediated suppression via prostaglandins and hydrogen peroxide. J Immunol 1982; 129: 1770–1774.PubMedGoogle Scholar
  172. 172.
    Fisherman EW. Does the allergic diathesis influence malignancy? J Allergy 1960; 31: 74–78.PubMedGoogle Scholar
  173. 173.
    Flodgren P, Sjogren HO. Influence in vitro on NK and K-cell activities by cimetidine and indomethacin with and without simultaneous exposure to interferon. Cancer Immunol Immunother 1985; 19: 28–34.PubMedGoogle Scholar
  174. 174.
    Florentin I, Kraus L, Mathe G, Hadden JW. In vivo study in mice of the immunopharmacological properties of NPT-15392. In: Serrou BRosenfeld CDaniels JBSaunders JP, eds. Current concepts of human immunology and cancer Amsterdam: Elsevier Biomedical, 1982: 463–469.Google Scholar
  175. 175.
    Forbes JT, Greco FA, Oldham RK. Human natural cellmediated cytotoxicity: II. Levels in neoplastic disease. Cancer Immunol Immunother 1982; 11: 147–153.Google Scholar
  176. 176.
    Ford RJ, Tsao J, Kouttab NM, et al. Association of an interleukin abnormality with the T-cell defect in Hodgkin’s disease. Blood 1984; 64: 386–392.PubMedGoogle Scholar
  177. 177.
    Fracchia A, Pacetti M, Barberis M, et al. Determination of T-lymphocyte subpopulations in patients with lung cancer. A comparison between lung lavage and peripheral blood by monoclonal antibodies and flow cytometry. Respiration 1987; 51: 3,161–169.PubMedGoogle Scholar
  178. 178.
    Frydecka I. Natural killer-cell activity during the course of disease in patients with Hodgkin’s disease. Cancer 1985;56:2799–2803.PubMedGoogle Scholar
  179. 179.
    Fujisama T, Yamaguchi Y, Kimura H, et al. Adjuvant immunotherapy of primary resected lung cancer with transfer factor. Cancer 1984; 54: 663–669.Google Scholar
  180. 180.
    Fujisawa T, Yamaguchi Y, Kimura H. Transfer factor in restoration and cell-mediated immunity in lung cancer patients. Jpn J Surg 1983; 13: 304–311.PubMedGoogle Scholar
  181. 181.
    Fuks Z, Strober S, Kaplan HS. Interaction between serum factors and T-lymphocytes in Hodgkin’s disease. N Eng Med 1976; 295: 1273–1278.Google Scholar
  182. 182.
    Fuks Z, Strober W, Bobrove AM, et al. Long-term effects of radiation on T- and B-lymphocytes in peripheral blood of patients with Hodgkin’s disease. J Clin Invest 1976; 58: 803–814.PubMedGoogle Scholar
  183. 183.
    Garay GE, Pavlovsky S, Sasiain MC, et al. Immunocompetence and prognosis in children with acute lymphoblastic leukemia: Combination of two different maintenance therapies. Med Pediatr Oncol 1976; 2:403–415.PubMedGoogle Scholar
  184. 184.
    Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency disease: a literature review. Cancer 1971;28:89–98.PubMedGoogle Scholar
  185. 185.
    Geffner JR, Serebrinsky G, Isturiz MA. Normal human serum restores the expression of Fc8 receptors in immune complex: blocked human mononuclear cells. Immunology1986; 59: 239–243.PubMedGoogle Scholar
  186. 186.
    Gilbert HA, Kagan AR, Miles J, et al. Delayed hypersensitivity in patients treated by curative radiotherapy. Its relation to tumor response and short-term survival. J Surg Oncol 1978; 10: 73–77.Google Scholar
  187. 187.
    Giulivi A, Cilano L, Roncoroni L, et al. Effects of cimetidine on in vitro transformation of peripheral monocytes to macrophages in healthy volunteers and cancer patients. Int J Immunopharmacol 1986; 8: 5; 517–523.PubMedGoogle Scholar
  188. 188.
    Goldenberg GJ, Brandes LJ, Lau WH, et al. Cooperative trial of immunotherapy for nasopharyngeal carcinoma with transfer factor from donors with Epstein-Barr virus antibody activities. Cancer Treat Rep 1985; 69: 761–767.PubMedGoogle Scholar
  189. 189.
    Goldrosen MH, Han T, Jung D, et al. Impaired lymphocyte blastogenic response in patients with colon adenocarcinoma: effects of disease and age. J Surg Oncol 1977; 9: 229–234.PubMedGoogle Scholar
  190. 190.
    Goldsmith HS, Levin AG, and Southam CM. A study of cellular responses in cancer patients by quantitative and qualitative Rebuck tests. Surg Forum 1965; 16: 102–104.PubMedGoogle Scholar
  191. 191.
    Goldstein AL, Low TLK, Thurman GB, et al. Thymosins and other hormone-like factors of the thymus gland. In: Mihich E, ed. Immunological cancer therapeutics. New York: Wiley, 1982: 137–190.Google Scholar
  192. 192.
    Golub SH, Rangel DM, Morton D. In vitro assessment of immunocompetence in patients with malignant melanoma. Int J Cancer 1977; 20: 873–880.PubMedGoogle Scholar
  193. 193.
    Goodwin JS, Messner RP, Bankhurst AD, et al. Prostaglandin-producing suppressor cells in Hodgkin’s disease. N Engl J Med 1977; 297: 963–968.PubMedGoogle Scholar
  194. 194.
    Gottlieb AA, Farmer JL, Matzura CT, et al. Modulation of human T-cell production of migration inhibitory lymphocytes by cytokines derived from human leukocyte dialysates.J Immunol 1984; 132: 1,256–260.PubMedGoogle Scholar
  195. 195.
    Green AA, Borella L. Immunologic rebound after cessation of long-term chemotherapy in acute leukemia. II. In vitro response to phytohemagglutinin and antigens by peripheral blood and bone marrow lymphocytes. Blood 1973;42:99–110.PubMedGoogle Scholar
  196. 196.
    Grohn P, Heinonen E, Klefstrom P, Tarkkanen J. Adjuvant postoperative radiotherapy, chemotherapy and immunotherapy in stage III breast cancer. Cancer 1985; 54: 670–674.Google Scholar
  197. 197.
    Groveman DS, Borden EC. In vitro and in vivo effects of levamisole on monocyte chemotaxis in normal donors and patients with colorectal carcinoma. J Biol Response Mod 1983;2: 167–174.PubMedGoogle Scholar
  198. 198.
    Grzelak I, Olszewski WL, Engeset A. Decreased suppressor cell activity after surgery. J Clin Lab Immunol 1985; 16:201–205.PubMedGoogle Scholar
  199. 199.
    Grzelak I, Olszewski WL, Engeset A. Suppressor cell activity in peripheral blood in cancer patients after surgery. Clin Exp Immunol 1983; 51: 149–156.PubMedGoogle Scholar
  200. 200.
    Guiliano AE, Rangel D, Golub SH, et al. Serum-mediated immunosuppression in lung cancer. Cancer 1979; 43: 917–924.Google Scholar
  201. 201.
    Gupta S, Cunningham-Rundles S. Deficient concanavalin- A-induced suppressor cell activity in women with untreated breast cancer. J Clin Lab Immunol 1982; 9: 159–161.PubMedGoogle Scholar
  202. 202.
    Gupta S, Good RA. Subpopulations of human T-lymphocytes: II. Effect of thymopoietin, corticosteroids, and irradiation. Cell Immunol 1977; 34: 10–18.PubMedGoogle Scholar
  203. 203.
    Haas GS, Halperin E, Doseretz D, et al. Differential recovery of circulating T-cell subsets after nodal irradiation for Hodgkin’s disease. J Immunol 1984; 132: 1026–1030.PubMedGoogle Scholar
  204. 204.
    Hadden JW. Chemically-defined immunotherapeutic drugs under development for the treatment of cancer. In: Serrou BRosenfeld CDaniels JCSaunders JP, eds. Current concepts in human immunology and cancer immunomodulation Amsterdam: Elsevier Biomedical, 1982:439–448.Google Scholar
  205. 205.
    Hadden JW. Recent advances in the preclinical and clinical immunopharmacology of interleukin-2: emphasis on IL-2 as an immunorestorative agent. Cancer Detect Prev 1988; 12: 537–552.PubMedGoogle Scholar
  206. 206.
    Hadjipetrou-Kourounakis L, Manikou H, Tsougranis A. Restoration of immunosuppression in lung cancer by normal sera. J Clin Lab Immunol 1985; 16: 149–153.PubMedGoogle Scholar
  207. 207.
    Haim N, Meidav A, Samuelly B, et al. Prostaglandinrelated and adherent cell suppressor system in apparently cured Hodgkin’s disease patients. J Biol Response Mod 1984;3:219–225.PubMedGoogle Scholar
  208. 208.
    Hakim AA. Peripheral blood lymphocytes from patients with cancer lack interleukin-2 receptors. Cancer 1988; 61:4,689–701.PubMedGoogle Scholar
  209. 209.
    Halili M, Bosworth J, Romney S, et al. The long-term effect of radiotherapy on the immune status of patients cured of a gynecologic malignancy. Cancer 1976; 37: 2875–2878.PubMedGoogle Scholar
  210. 210.
    Hall HRS, Goldstein AL. The endocrine thymus. In: Becker KC, ed. Principles and practice of endocrinology and metabolism. New York Lippincott, 1990.Google Scholar
  211. 211.
    Han T, Takita H. Indomethacin-mediated enhancement of lymphocyte response to mitogens in healthy subjects and lung cancer patients. Cancer 1980; 46: 2416–2420.PubMedGoogle Scholar
  212. 212.
    Han T. Studies of correlation of lymphocyte response to phytohemagglutinin with the clinical and immunologic status in chronic lymphocytic leukemia. Cancer 1973; 31 : 280–285.PubMedGoogle Scholar
  213. 213.
    Han T, Nemoto T, Ledesma EJ, Bruno S. Enhancement of T-lymphocyte response to mitogens by indomethacin in breast and colorectal cancer patients. Int J Immunopharmacol 1983; 5: 11–15.PubMedGoogle Scholar
  214. 214.
    Herr HW. Adherent suppressor cells in the blood of patients with bladder cancer. J Urol 1981; 126: 457–460.PubMedGoogle Scholar
  215. 215.
    Hakim AA. Lipid-like agent from human neoplastic cells suppresses cell-mediated immunity. Cancer Immunol Immunother 1980; 8: 1330.Google Scholar
  216. 216.
    Han T, Takita H. Immunologic impairment in bronchogenic carcinoma: A study of lymphocyte response to phytohemagglutinin. Cancer 1972; 30: 616–620.PubMedGoogle Scholar
  217. 217.
    Hanaue H, Kim DY, Machimura T, et al. Hemolytic streptococcus preparation Ok-432: Beneficial adjuvant therapy in recurrent gastric carcinoma. Tokai J Exp Clin Med 1987; 12:4,209–214.PubMedGoogle Scholar
  218. 218.
    Hancock BW, Bruce L, Sokol RJ, Clark A. Transfer factor in Hodgkin’s disease: A randomized clinical and immunological study. Eur J Cancer Clin Oncol 1988; 24: 5; 929–933.PubMedGoogle Scholar
  219. 219.
    Hancock BW, Bruce L, Whitham MD, Ward AM. The effects of radiotherapy on immunity in patients with cured localized carcinoma of the cervix uteri. Cancer 1984; 53: 884–887.PubMedGoogle Scholar
  220. 220.
    Harris J, Copeland D. Impaired imunoresponsiveness in tumor patients. Ann NY Acad Sci 1974; 230: 56–85.PubMedGoogle Scholar
  221. 221.
    Harris JE, DeBoer KP, Vahey AC, Braun DP. The measurement of leukocyte subsets in the peripheral blood of cancer patients using monoclonal antibody reagents. Med Pediatr Oncol 1982; 10: 185–194.PubMedGoogle Scholar
  222. 222.
    Harris JE, Stewart THM. Recovery of mixed lymphocyte reactivity (MLR) following cancer chemotherapy in man. In: Schwartz MR, ed. Proceedings of the Sixth Leukocytes Culture Conference. New York: Academic Press, 1979: 555–580.Google Scholar
  223. 223.
    Haskell CM. Immunologic aspects of cancer chemotherapy. Ann Rev Pharmacol Toxicol 1977; 17: 179–195.Google Scholar
  224. 224.
    Hausman MS, Brossman SA, Snyderman R, et al. Defective monocyte function in patients with genitourinary carcinoma. J Natl Cancer Inst 1975; 55: 1047–1054.PubMedGoogle Scholar
  225. 225.
    Hayashi Y, Nishida T, Yoshida H, et al. Peripheral Tgamma lymphocyte population in head and neck cancer. Cancer Immunol Immunother 1984; 17: 160–164.PubMedGoogle Scholar
  226. 226.
    Heal JM, Chuang C, Blumberg N. Perioperative blood transfusions and prostate cancer recurrence and survival. Am J Surg 1988; 156: 374–379.PubMedGoogle Scholar
  227. 227.
    Hernandez JL, Sanz M, Crisi CD, et al. Lymphocyte subpopulations in colorectal cancer-postoperative evaluation. Allergy Immunopathol 1978; 6: 339–344.Google Scholar
  228. 228.
    Hersey P, Bindon C, Czerniecki M, et al. Inhibition of interleukin-2 production by factors released from tumor cells. J Immunol 131: 2837–2842.Google Scholar
  229. 229.
    Hersh EM, Gutterman JU, Mavligit GM, Reed RC. Immunologic aspects of chemotherapy. In: Cancer Chemotherapy-Fundamental Concepts and Recent Advances 1975; pp 279–294; Yearbook medical, Chicago.Google Scholar
  230. 230.
    Hersh EM. Vinca alkaloids. In: Sartorelli ACJohns DG, eds. Antineoplastic and immunosuppressive agents, part I.NewYork: SpringerVerlag, 1974: 601–602.Google Scholar
  231. 231.
    Hersh EM, Gutterman JU, Mavligit GM. Immunotherapy of leukemia. Med Clin North Am 1976; 60: 1019–1042.PubMedGoogle Scholar
  232. 232.
    Hersh EM, Gutterman JU, Mavligit GM, et al. Serial studies of immunocompetence of patients undergoing chemotherapy for acute leukemia. J Clin Invest 1974; 54: 401–408.PubMedGoogle Scholar
  233. 233.
    Hersh EM, Whitecan JP Jr, McCredie JB, et al. Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. N Engl J med 1971; 285: 1211–1216.PubMedGoogle Scholar
  234. 234.
    Hersh EM, Irwin WS. Blastogenic responses of lymphocytes from patients with untreated and treated lymphomas. Lymphology 1969; 2: 150–160.PubMedGoogle Scholar
  235. 235.
    Hersh EM.Immunosuppressive agents. In: Sartorelli ACJohns DG, eds. Antineoplastic and immunosuppressive agents, part I. New York: Springer Verlag, 1974: 555–576.Google Scholar
  236. 236.
    Hersh EM, Oppenheim J. Inhibition of in vitro lymphocyte transformation during chemotherapy in man. Cancer Res 1979; 27:98–105.Google Scholar
  237. 237.
    Herskovic A, Bauer M, Seydel G, et al. Postoperative thoracic irradiation with or without levamisole in nonsmall- cell lung cancer: results of a radiation therapy oncology group study. Int J Radiation Oncology Biol Phys 1988; 14: 1; 37–42.Google Scholar
  238. 238.
    Hilal EY, Wanebo HJ, Pinsky CM, et al. Immunologic evaluation and prognosis in patients with head and neck cancer. Am J Surg 1977; 134: 68–73.Google Scholar
  239. 239.
    Hilgard P, Pohl J, Stekar J, Voegeli R. Oxazaphosphorines as biological response modifiers: experimental and clinical perspective. Cancer Treat Rev 1985; 12: 155–162.PubMedGoogle Scholar
  240. 240.
    Hillinger SM, Herzig GP. Impaired cell-mediated immunity in Hodgkin’s disease mediated by suppressor lymphocytes and monocytes. J Clin Invest 1978; 61: 1620–1627.PubMedGoogle Scholar
  241. 241.
    Hirsh B, Johnson JT, Rabin BS, Thearle PB. Immunostimulation of patients with head and neck cancer. In vitro and preliminary clinical experience. Arch Otolaryngol 1983;109:298–301.Google Scholar
  242. 242.
    Hirshaut Y, Pinsky CM, Frydecka I, et al. Effect of shortterm levamisole therapy on delayed hypersensitivity. Cancer 1980; 45:362–366.PubMedGoogle Scholar
  243. 243.
    Hoagland JG, Scoggin S, Giavazzi R, et al. Tumor-derived suppressor factors (TDSFs) in normal and neoplastic colon and rectum. J Surg Res 1986; 40: 5,467–474.PubMedGoogle Scholar
  244. 244.
    Hodgson WJB, Lowenfels AB. Blood transfusion and recurrence rates in colonic malignancy. Lancet 1982; 2: 1047.PubMedGoogle Scholar
  245. 245.
    Hojo H, Hashimoto Y. Cytotoxic cells induced in tumorbearing rats by a streptococcal preparation (OK-432). Gann 1981;72:62–69.Google Scholar
  246. 246.
    Holm G, Mellstedt H, Bjorkholm M, et al. Lymphocyte abnormalities in untreated patients with Hodgkin’s disease. Cancer 1976; 37: 751–762.PubMedGoogle Scholar
  247. 247.
    Holmes EC. Immunology of tumor-infiltrating lymphocytes. Ann Surg 1985; 201: 158–163.PubMedGoogle Scholar
  248. 248.
    Holmes E, Sibbitt WL, Bankhurst AD. Serum factors which suppress natural cytotoxicity in cancer patients. Int Arch AllergyApplImmunol 1986; 80: 39–43.PubMedGoogle Scholar
  249. 249.
    Holmes EC, Golub SH. Immunologic defects in lung cancer patients. J Thoracic Cardiovasc Surg 1976; 71: 161–168.Google Scholar
  250. 250.
    Hoon DSB, Bowker RJ, Cochran AJ. Suppressor-cell activity in melanoma-draining lymph nodes. Cancer Res 1987; 47: 1529–1533.PubMedGoogle Scholar
  251. 251.
    Hoon DSB, Korn EL, Cochran AJ. Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans. Cancer Res 1987; 47: 1740–1744.PubMedGoogle Scholar
  252. 252.
    Hoon DS, Irie RF, Cochran AJ. Gangliosides from human melanoma immunomodulate responses of T-cells to interleukin-2. Cell Immunol 1988; 111: 2,410–419.PubMedGoogle Scholar
  253. 253.
    Horiguchi M, Saito A, Sonoda H. A gastric cancer showing marked improvement (stage IV) with lentinan immunotherapy and 5-FU, MMC-chemotherapy. Gan To KagakuRyoho 1988; 15: 6, 1973–1977.PubMedGoogle Scholar
  254. 254.
    Horrino N. Impaired PWM-induced polyclonal B-cell activation in patients with malignancies treated with various intermittent combination chemotherapies including doxorubicin. Cancer 1982; 50: 659–667.Google Scholar
  255. 255.
    Hortobagyi GN, Hersh EM, Papadopoulos EJ, et al. Initial clinical studies with copovithane. J Biol Response Mod 1986;5:319–329.PubMedGoogle Scholar
  256. 256.
    Hsu CC, Logerfo P. Correlation between serum alpha globulin and plasma inhibitory effect of PHA-stimulated lymphocytes in colon cancer patients. Proc Soc Exp Biol Med1972 139: 575–578.PubMedGoogle Scholar
  257. 257.
    Huang AT, Mold NG, Fisher Sr, et al. A prospective study of squamous head and neck carcinoma. Cancer 1987; 59: 1721–1726.PubMedGoogle Scholar
  258. 258.
    Hubbard GW, Wanebo H, Fukuda M, Pace R. Defective suppressor-cell activity in cancer patients: A defect in immune regulation. Cancer 1981; 47: 2177–2184.PubMedGoogle Scholar
  259. 259.
    Ninneman JL. Melanoma-associated immunosuppression through B-cell activation of suppressor T-cells. J Immunol 1978; 120:1573–1579.Google Scholar
  260. 260.
    Hughes NR. Serum concentrations of gamma G, gamma A and gamma M immunoglobulins in patients with carcinoma, melanoma, and sarcoma. J Natl Cancer Inst 1971; 46: 1015–1028.PubMedGoogle Scholar
  261. 261.
    Humphrey LJ, Humphrey MA, Singla O, Volenec FJ. Immunologic responsiveness of patients with cancer: relationship to tumor type, stage and prognosis. Ann Surg 1981; 193:574–578.PubMedGoogle Scholar
  262. 262.
    Hyman GA. Increased incidence of neoplasia in association with chronic lymphocytic leukemia. Scand J Haematol 1969; 6: 99–104.PubMedGoogle Scholar
  263. 263.
    Iaffaioli RV, Frasci G, Tortora G, et al. Effect of thymic extract ’thymostimulin’ on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer. Thymus 1988; 12: 69–75.PubMedGoogle Scholar
  264. 264.
    Ichimura O, Suzuki S, Saito M, et al. Augmentation of interleukin-1 and interleukin-2 production by OK-432. Int JImmunopharmacol 1985; 7: 263–270.Google Scholar
  265. 265.
    Inagaki T, Morise K, Matsunaga H. Effects of endoscopic intratumoral injection of lentinan in patients with gastric cancer. Gan To Kagaku Ryoho 1988; 15: 2,319–324.PubMedGoogle Scholar
  266. 266.
    Intergropu 5-FU/levamisole study positive; untreated arms stopped, clinical alert sent. Clin Trials - Clin Cancer Lett 1989; October.Google Scholar
  267. 267.
    Israel L, Mugica J, Chahinian PH. Prognosis of early bronchogenic carcinoma: Survival cures of 451 patients after resection of lung cancer in relation to the results of preoperative tuberculin skin test. Biomed Exp 1973; 19: 68–72.Google Scholar
  268. 268.
    Itoh K, Pellis NR, Balch C. Monocyte-dependent serumborne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients. Cancer Immunol Immunother 1989; 29: 57–62.PubMedGoogle Scholar
  269. 269.
    Jacobs D, Houri M, Landon J, Merret TG. Circulating levels of immunoglobulin E in patients with cancer. Lancet 1972; 2: 1059–1061.PubMedGoogle Scholar
  270. 270.
    Jacobson DR, Zolla-Pazner S. Immunosuppression and infection in multiple myeloma. Sem Oncol 1986; 13: 3; 282–290.Google Scholar
  271. 271.
    Jansen HM, The TH, deGast GC, et al. The primary immune response of patients with different stages of squamous-cell bronchial carcinoma. Thorax 1978; 33: 755–760.PubMedGoogle Scholar
  272. 272.
    Jenkins VK, Ray P, Ellis HN, et al. Lymphocyte response in patients with head and neck cancer: effect of clinical stage and radiotherapy. Arch Otolaryngol 1976; 102: 596–600.PubMedGoogle Scholar
  273. 273.
    Jenkins VK, Griffiths CM, Ray P, et al. Radiotherapy and head and neck cancer. Role of lymphocyte response and clinical stags . Arch Otolaryngol 1980; 106: 414–418.PubMedGoogle Scholar
  274. 274.
    Jerrells TR, Dean JH, Richardson GL, et al. Role of suppressor cells in depression of in vitro lymphoproliferative responses of lung cancer and breast cancer patients. J Natl Cancer Inst 1978; 61: 1001–1009.PubMedGoogle Scholar
  275. 275.
    Jerrells TR, Dean JH, Herberman RB. Relationship between T-lymphocyte levels and lymphoproliferative responses to mitogens and alloantigens in lung and breast cancer patients. Int J Cancer 1978; 21: 282–290.PubMedGoogle Scholar
  276. 276.
    Job G, Pfeundschuh M, Bauer M, et al. The influence of radiation therapy on T-lymphocyte subpopulations defined by monoclonal antibodies. Int J Radiat Oncol Biol Phys 1984; 10: 2077–2081.PubMedGoogle Scholar
  277. 277.
    Joensun H, Nordman E, Toivanen A. Long-term effect of levamisole on the immune functions in melanoma patients. Strahlenther Onkol 1986; 162: 12,753–756.Google Scholar
  278. 278.
    Joensun H, Toivanen A, Nordman E. Effect of tamoxifen on immune function. Cancer Treat Rep 1986; 7: 3, 381–382.Google Scholar
  279. 279.
    Johnson JD, Summersgill JT, Raff MJ. The in vitro effects of methotrexate on the phagocytosis and intracellular killing of Staphylococcus aureus by human neutrophils. Cancer 1986; 57:2343–2345.PubMedGoogle Scholar
  280. 280.
    Johnston-Early A, Cohen MH, Fossieck BE, et al. Delayed hypersensitivity skin testing as a prognostic indicator in patients with small-cell lung cancer. Cancer 1983; 52: 1395–1400.PubMedGoogle Scholar
  281. 281.
    Jondal M, Merrill J, Ullberg M. Monocyte-induced human natural killer cell suppression followed by increased cytotoxic activity during short-term in vitro culture in autologous serum. Scand J Immunol 1981; 14: 555–563.PubMedGoogle Scholar
  282. 282.
    Jones KD, Whitehead RH, Grimshaw D, Hughes LE. Lymphocyte response to PHA and patient response to chemotherapy in breast cancer. Clin Oncol 1980; 6: 159–166.PubMedGoogle Scholar
  283. 283.
    Jones SE, Griffith K, Dombrowski P, Gaines JA. Immunodeficiency in patients with non-Hodgkin’s lymphomas. Blood 1977; 49: 335–344.PubMedGoogle Scholar
  284. 284.
    Jose DG, Seshadri R. Circulating immune complexes in neuroblastoma: direct assay and role in blocking specific cellular immunity. Int J Cancer 1974; 13: 824–838.PubMedGoogle Scholar
  285. 285.
    Jubert AV, Lee ET, Hersh EM, McBridge CM. Effects of surgery, anesthesia and intraoperative blood loss on immunocompetence. J Surg Res 1973; 15: 399–403.PubMedGoogle Scholar
  286. 286.
    Jung TT, Berlinger NT, Juhn SK. Prostaglandins in squamous-cell carcinoma of the head and neck: a preliminary study. Laryngoscope 1985; 95: 307–312.PubMedGoogle Scholar
  287. 287.
    Kadish AS, Doyle AT, Steinhaur EH, Ghossein NA. Natural cytotoxicity and interferon production in human cancer: deficient natural killer activity and normal interferon production in patients with advanced disease. J Immunol 1981 127: 1817–1822.PubMedGoogle Scholar
  288. 288.
    Kaneko T. Effects of lentinan on cytotoxic functions of human lymphocytes. Immunopharmacol Immunotoxicol 1988; 10:2,157–163.PubMedGoogle Scholar
  289. 289.
    Kaplan HS. Hodgkin s disease. Cambridge Mass: Harvard University Press, 1980.Google Scholar
  290. 290.
    Kaplan HS. Hodgkin’s disease. Cambridge, Mass. Harvard University Press, 1980.Google Scholar
  291. 291.
    Karavodin LM, Guilliano AE, Golub SH. T-lymphocyte subsets in patients with malignant melanoma. Cancer Immunol Immunother 1981; 11: 251–254.Google Scholar
  292. 292.
    Kaszubowski PA, Husky G, Tung KS, Williams RC Jr. Tlymphocyte subpopulations in peripheral blood and tissues of cancer patients. Cancer Res 1980; 40: 4684–4657.Google Scholar
  293. 293.
    Katz AE. Immunobiologic staging of patients with carcinoma of the head and neck. Laryngoscope 1983; 93: 445–463.PubMedGoogle Scholar
  294. 294.
    Kawaguchi T, Suematsu M, Koizumi HM, et al. Activation of macrophage function by intraperitoneal administration of the streptococcal anti-tumor agent OK-432. Immunopharmacology 1983; 6: 1077–1089.Google Scholar
  295. 295.
    Kay RG, Mason BH, Stephans EJ, et al. Levamisole in primary breast cancer: A controlled study in conjunction with L-phenylalanine mustard. Cancer 1983; 51: 1992–1997.PubMedGoogle Scholar
  296. 296.
    Keller SM, Groshen S, Martini N, Kaiser LR. Blood transfusion and lung cancer recurrence. Cancer 1988; 62: 606–610.PubMedGoogle Scholar
  297. 297.
    Kenady DE, Chretien PB, Potvin C, et al. Effect of thymosin in vitro on T-cell levels during radiation therapy. Cancer 1972; 39: 642–652.Google Scholar
  298. 298.
    Kerman RH, Stefani SS. Phytohemagglutinin stimulation of lymphocytes in lung cancer patients. Oncology 1977; 34: 10–12.PubMedGoogle Scholar
  299. 299.
    Kerman RH, Smith R, Stefani SS. Active T-rosette forming cells in the peripheral blood of cancer patients. Cancer Res 1976; 36: 3274–3280.PubMedGoogle Scholar
  300. 300.
    Khoo SK, Whitaker SV, Jones IS, Thomas DA. Levamisole as adjuvant to chemotherapy of ovarian cancer. Results of a randomized trial and 4-year follow-up. Cancer 1984; 54: 986–990.PubMedGoogle Scholar
  301. 301.
    Kikuchi Y, Kizawa I, Oomori K, et al. Effects of cimetidine on interleukin-2 production by peripheral blood lymphocytes in advanced ovarian carcinoma. Eur J Cancer Clin Oncol 1988; 24: 7,1185–1190.PubMedGoogle Scholar
  302. 302.
    Kirsh MM, Orringer MB, McAuliffe S, et al. Transfer factor in the treatment of carcinoma of the lung. Ann ThoracSurg 1984; 38: 140–145.PubMedGoogle Scholar
  303. 303.
    Klefstrom P, Holsti P, Grohn P, et al. Levamisole in the treatment of stage II breast cancer. Five-year follow-up of a randomized double-blind study. Cancer 1985; 55: 2753–2757.PubMedGoogle Scholar
  304. 304.
    Klefstrom P. Combination of levamisole immunotherapy and polychemotherapy in advanced breast cancer. Cancer Treat Rep 1980;64:65–72.PubMedGoogle Scholar
  305. 305.
    Klefstrom P, Nuortio L, Taskinen E. Post-operative radiation therapy and adjuvant chemoimmunotherapy in breast cancer. Aspects of timing and immune competence. Acta Radiol [Oncol] 1986; 25: 3; 161–166.Google Scholar
  306. 306.
    Klefstrom P, Grohn P, Heinonen E, et al. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. II. Five-year results and influence of levamisole. Cancer 1987; 60: 5,936–942.PubMedGoogle Scholar
  307. 307.
    Klefstrom P, Holsti P, Grohn P, Heinonem E. Combination of levamisole immunotherapy with conventional treatments in breast cancer. In: Terry WD, ed. Proceedings of Second International Conference on Immunotherapy of Cancer. Bethesda, Md: 19 : 4128-4130.Google Scholar
  308. 308.
    Kleinerman ES, Zwelling LA, Schwartz R, et al. Effect of L-phenylalanine mustard, adriamycin and actinomycin D, and 4’-(9-acridinylamino) methanesulfon-m-anisidide on naturally occurring human spontaneous monocytemediated cytotoxicity. Cancer Res 1982; 42: 1692–1695.PubMedGoogle Scholar
  309. 309.
    Koba F, Akiyoshi T, Tsuji H. Natural killer-cell activity in the perigastric lymph nodes from patients with gastric carcinoma or benign lesions. J Clin Lab Immunol 1987; 23:4; 191–195.PubMedGoogle Scholar
  310. 310.
    Kova J, Ninger E, Zemanov D, Lauerov P. A prospective study of lymphocyte responses to phytohemagglutinin in melanoma (lack of prognostic value of correlation with minimal tumor burden). Neoplasma 1980; 27: 575–582.Google Scholar
  311. 311.
    Kratikanont P, deShazo RD, Banks DE, Chapman Y. Cytotoxic cell function in bronchogenic carcinoma. Chest 1098; 92: 1,90–94.Google Scholar
  312. 312.
    Kraus S, Comas F, Perez C, et al. Treatment of inoperable non-small-cell carcinoma of the lung with radiation therapy, with or without levamisole. Am J Clin Oncol 1984;7:405–412.Google Scholar
  313. 313.
    Kreienberg R, Boerner D, Melchert F, and Lemmell EM. Reduction of the immunosuppressive action of chemotherapeutics in patients with mammary carcinoma byAzimexon. J Immunopharmacol 1983; 5: 49–64.PubMedGoogle Scholar
  314. 314.
    Kripke ML. Immunoregulation of carcinogenesis: Past, present, and future. J Natl Cancer Inst 1988; 80:122–121.Google Scholar
  315. 315.
    Krown S, Pinsky CM, Wanebo HJ, et al. Immunologic reactivity and prognosis in breast cancer. Cancer 1980; 46:1746–1752.PubMedGoogle Scholar
  316. 316.
    Kumano N, Suzuki S, Oizumi K, et al. Imbalance of T-cell subsets in cancer patients and its modification with bestatin, a small molecular immunomodifier. Tohoku J Exp Med 1985; 147: 125–133.PubMedGoogle Scholar
  317. 317.
    Kurosu Y, Tanaka N, Furusho Y, Morita K. Cimetidinemediated augmentation of lymphocyte responses to phytohemagglutinin in gastric cancer patients. Jpn J Clin Oncol 1989; 19: 1; 56–61.PubMedGoogle Scholar
  318. 318.
    Lauria F, Raspadori D, Tura S. Effect of a thymic factor on T-lymphocytes in B-cell chronic lymphocytic leukemia: In vitro and in vivo studies. Blood 1984; 64: 667–671.PubMedGoogle Scholar
  319. 319.
    Lauria F, Foa R, Gobbi M, et al. Increased proportion of suppressor/cytotoxic (OKT8+) cells in patients with Hodgkin’s disease in long-lasting remission. Cancer 1983;52:1385–1388.PubMedGoogle Scholar
  320. 320.
    Lauria JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989; 7: 1447–1456.Google Scholar
  321. 321.
    Laurie J, Moertel C, Fleming T, et al. Surgical adjuvant therapy of poor prognosis colorectal cancer with levamisole alone or combined levamisole and 5- fluorouracil (5-FU) (Abstract). ProcASCO 1986; 5:81.Google Scholar
  322. 322.
    Lawrence HS. The transfer in humans of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leukocytes. J Clin Invest 1955; 34: 219– 230.Google Scholar
  323. 323.
    Lee ET, Ishmael R, Bottomley RH, Murray JL. An analysis of skin tests and their relationship to recurrence and survival in stage III and stage IV melanoma patients. Cancer 1982; 49: 2336–2341.PubMedGoogle Scholar
  324. 324.
    Lee YT. Delayed cutaneous hypersensitivity, lymphocyte count, and blood tests, in patients with breast carcinoma. J Surg Oncol 1984; 27: 135–140.PubMedGoogle Scholar
  325. 325.
    Lee AKY, Rowley M, MacKay IR. Antibody-producing capacity in human cancer. Br J Cancer 24: 454–463.Google Scholar
  326. 326.
    Lee YT, Sparks FC, Eilber FR, Morton DL. Delayed cutaneous hypersensitivity and peripheral lymphocyte counts in patients with advanced cancer. Cancer 1975; 35: 748–755.PubMedGoogle Scholar
  327. 327.
    Leibler GA, Concannon JP, Magorern GJ, et al. Immunoprofile studies for patients with bronchogenic carcinoma. JThorac Cardiovasc Surg 1911; 74: 506–518.Google Scholar
  328. 328.
    Levin RH, Landy M, Frei E. The effect of 6-mercaptopurine on immune response in man. N Engl J Med 1964; 271: 16–22.PubMedGoogle Scholar
  329. 329.
    Levo Y, Rotter V, Ramot B. Restoration of cellular immune response by levamisole in patients with Hodgkin’s disease. Biomedicine 1975; 23: 198–200.PubMedGoogle Scholar
  330. 330.
    Levy S, Herberman R, Lippman M, d’Angelo T. Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer.J Clin Oncol 1987; 5: 3; 348–353.PubMedGoogle Scholar
  331. 331.
    Lewinski UH, Mavligit GM, Hersh EM. Cellular immune modulation after a single high dose of levamisole. Cancer 1980;46:2185–2194.PubMedGoogle Scholar
  332. 332.
    Liberati AM, Bragia M, Edwards BS, et al. Immunorestorative properties of thymostimulin (TS) in patients with Hodgkin’s disease in clinical remission. Cancer Immunol Immunother 1985; 19: 136–141.PubMedGoogle Scholar
  333. 333.
    Liberata AM, Ballatori E, Fizzotti M, et al. A randomized trial to evaluate the immunorestorative properties of thymostimulin in patients with Hodgkin’s disease in complete remission. Cancer Immunol Immunother 1988; 26: 87–93.Google Scholar
  334. 334.
    Liberata AM, Voekel JG, Borden EC, et al. Influence of non-specific immunologic factors on prognosis in advanced bronchogenic carcinoma. Cancer Immunol Immunother 1982; 13: 140–144.Google Scholar
  335. 335.
    Lichtenstein A, Zighelboim J, Dorey R, et al. Comparison of immune derangements in patients with different malignancies. Cancer 1980; 45: 2090–2095.PubMedGoogle Scholar
  336. 336.
    Lin CC, Kuo YC, Huang WC, Lin CY. Natural killer-cell activity in lung cancer patients. Chest 1987; 92: 6, 1022–1024.PubMedGoogle Scholar
  337. 337.
    Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 1980;605:33–91.PubMedGoogle Scholar
  338. 338.
    Loutfi A, Shakr A, Jerry M, et al. Double-blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. Clin Invest Med 1987; 10:4,325–328.PubMedGoogle Scholar
  339. 339.
    Ludwig CU, Hartmann D, Landmann R, et al. Unaltered immunocompetence in patients with nondisseminated breast cancer at the time of diagnosis. Cancer 1985; 55: 1673–1678.PubMedGoogle Scholar
  340. 340.
    Lundy J, Raaf JH, Deakins S, Wanebo HJ. The acute and chronic effects of alcohol on the human immune system. Surg Gynecol Obstet 1975; 141: 212–218.PubMedGoogle Scholar
  341. 341.
    Luzi G, Troopea F, Seminara R, et al. Clinical and immunological evaluation in non-resectable lung cancer patients treated with thymostimulin. In: Byrom NAHobbs JR, eds. Thymic factor therapy. New York: Raven Press, 1984: 309–320.Google Scholar
  342. 342.
    Maca RM, Panje WR. Indomethacin-sensitive suppressor- cell activity in head and neck cancer patients preand post-irradiation therapy. Cancer 1982; 50:483–489.PubMedGoogle Scholar
  343. 343.
    Macchiarini P, Danesi R, DelTacca M, Angeletti CA. Effects of thymostimulin on chemotherapy-induced toxicity and long-term survival in small-cell lung cancer patients. Anticancer Res 1989; 9: 1; 193–196.PubMedGoogle Scholar
  344. 344.
    Mackay JR, Goodyear MD, Riglar C, et al. Effect on immunologic and other indices of adjuvant cytotoxic chemotherapy including melphalan in breast cancer. Cancer 1984; 53: 2619–2627.PubMedGoogle Scholar
  345. 345.
    Maguire LC, Roszman TL, Lackey S. Failure of cimetidine as an immunomodulator in cancer patients and normal subjects. South Med J 1985; 78: 1078–1080.PubMedGoogle Scholar
  346. 346.
    Mahaley MS Jr, Brooks WH, Roszman TL, et al. Immunobiology of primary intracranial tumors. I. Studies of the cellular immunity of brain tumor patients. J Neurosurg 1977; 46:467–476.PubMedGoogle Scholar
  347. 347.
    Maisel RH, Ogura JH. Dinitrochlorobenzene skin sensitization and peripheral lymphocyte count: predictors of survival in head and neck cancer. Ann Otol Rhino I Laryngol 1976; 85:517–522.Google Scholar
  348. 348.
    Mandel MA, Dvorak K, Decasse JJ. Salivary immunoglobulins in patients with oropharyngeal and bronchopulmonary cancer. Cancer 1973;31:1408–1413.PubMedGoogle Scholar
  349. 349.
    Mandeville R, Lamoureux G-T, Poisson SL, Poisson R. Biological markers and breast cancer: a multiparameter study. II. Depressed immune competence. Cancer 1982; 50: 1280–1288.PubMedGoogle Scholar
  350. 350.
    Mantovani G, Floris C, Maccio A, et al. Role of interleukin- 2 (IL-2) in cancer-related immune deficiency: In vitro response to IL-2, production of IL-2, and IL-2 receptor expression in patients with advanced cancer. Cancer Detect Prev 1988; 12: 149–159.PubMedGoogle Scholar
  351. 351.
    Marshall ME, Mendelsohn L, Butler K, et al. Treatment of metastatic renal cell carcinoma with coumarin (1, 2- benzopyrone) and cimetidine: a pilot study. J Clin Oncol 1987; 5: 6; 862–866.PubMedGoogle Scholar
  352. 352.
    Marshall ME, Riley LK, Rhoades J, et al. Effects of coumarin (1, 2-benzopyrone) and cimetidine on peripheral blood lymphocytes, natural killer cells, and monocytes in patients with advanced malignancies. J Biol Response Mod 1989; 8: 1, 62–69.PubMedGoogle Scholar
  353. 353.
    Martelli MF, Velardi A, Rambotti P, et al. The in vivo effect of a thymic factor (thymostimulin) in immunologic parameters of patients with untreated Hodgkin’s disease. Cancer 1982; 50:490–497.PubMedGoogle Scholar
  354. 354.
    Mastrangelo MJ, Berd D, Maguire H Jr. Cell-mediated immunity: The immunoaugmenting effects of cancer chemotherapeutic agents. Sem Oncol 1986; 13: 2; 186–194.Google Scholar
  355. 355.
    Mathe G, Amiel JL, Schwarzenberg L, et al. Active immunotherapy for acute lymphoblastic leukemia. Lancet 1969; 1:697–699.PubMedGoogle Scholar
  356. 356.
    Mathe G. Do tuftsin and bestatin constitute a biopharmacological immunoregulatory system? Cancer Detect Prev Suppl 1987; 1:445–455.PubMedGoogle Scholar
  357. 357.
    Mathe G, Umezawa H, Misset JL, et al. Immunomodulating properties of bestatin in cancer patients. A phase II trial. Biomed Pharmacother 1986; 40: 10, 379–382.PubMedGoogle Scholar
  358. 358.
    Mavligit GM. Immunologic effects of cimetidine: potential uses. Pharmacotherapy 1987; 7: 120S–124S.PubMedGoogle Scholar
  359. 359.
    Mavligit GM, Raphael LS, Calvo DB III, Wong WL. Indomethacin-induced monocyte-dependent restoration of local graft-versus-host reaction among cells from cancer patients. J Natl Cancer Inst 1980; 65: 317–320.PubMedGoogle Scholar
  360. 360.
    McCredie JA, Macdonald HR. Antibody-dependent cellular cytotoxicity in cancer patients: Lack of prognostic value. Br J Cancer 1980; 41: 880–885.PubMedGoogle Scholar
  361. 361.
    McGeorge MB, Russel EC, Mohanakumar T. Immunologic evaluation of long-term effects of childhood ALL chemotherapy: Analysis of in vitro NK- and K-cell activities of peripheral blood lymphocytes. Am J Hematol 1982; 12: 19–27.PubMedGoogle Scholar
  362. 362.
    McGinnes K, Florence J, Penny R. The effect of radiotherapy on the natural killer (NK) cell activity of cancer patients. J Clin Immunol 1987; 7: 3,210–217.PubMedGoogle Scholar
  363. 363.
    Menconi E, Barzi A, Greco M, et al. Immunological profile of breast cancer patients in early of advanced disease. Experimentia 1979; 35: 820–822.Google Scholar
  364. 364.
    Merrin C, Han T. Immune responses in bladder cancer. J Urol 1974; 111: 170–172.PubMedGoogle Scholar
  365. 365.
    Messerschmidt GL, Henry DH, Snyder HW Jr, et al. Protein A immunoadsorption in the treatment of malignant disease. J Clin Oncol 1988; 6: 2; 203–212.PubMedGoogle Scholar
  366. 366.
    Metzher Z, Hoffeld JT, Oppenheim JJ. Evidence for the involvement of monocyte-derived toxic oxygen metabolites in the lymphocyte dysfunction of Hodgkin’s disease. Clin Exp Immunol 1981; 46: 313–320.Google Scholar
  367. 367.
    Micksche M, Cerni C, Kokron K, et al. Stimulation of the immune response in lung cancer patients by vitamin A. Oncology 1977; 34: 234–239.PubMedGoogle Scholar
  368. 368.
    Micksche M, Colot M, Kucera H. Radioimmunotherapy in advanced cervical cancer. In: Dubois JBSerrou BRosenfeld C, eds. Immunopharmacologic effects of radiation therapy. New York: Raven Press, 1981:499–518.Google Scholar
  369. 369.
    Mihich E. Biological response modifiers in cancer therapeutics: Potentialities and limitations. Cancer Detect Prev 1988; 12:531–535.PubMedGoogle Scholar
  370. 370.
    Mihich E, Ehreke MJ, Ishizuka M. Immunomodulation by antibiotics. In: Mihich ESakurai Y, eds. Biological responses in cancer, vol 3: immunomodulation by anticancer drugs. New York: Plenum Press, 1985: 71–73.Google Scholar
  371. 371.
    Miller HC, Vito C. Action of a thymic cytokine TsIF in reversing the autoimmune disease state of the MRL/lpr mouse. Mol Biother 1989; 1:4,213–217.PubMedGoogle Scholar
  372. 372.
    Miller LL, Spider LE, Allen RE, Minot DR. A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma. Cancer 1988; 61: 1543–1549.PubMedGoogle Scholar
  373. 373.
    Miller FR, Kataoka T. Interactions of antimetabolites with tumors and the immune system. In: Mihich ESakurai Y, eds. Biological responses in cancer, vol 3: immunomodulation by anti-cancer drugs. New York: Plenum Press, 1985:33–69.Google Scholar
  374. 374.
    Mitchell MS, Kempf RA, Harel W, et al. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 disseminated melanoma. J Clin Oncol 1988; 6: 3; 409–424.PubMedGoogle Scholar
  375. 375.
    Mitchell MS, Defonti RC. Immunosuppression by 5- fluorouracil. Cancer 1970; 26: 884–889.PubMedGoogle Scholar
  376. 376.
    Mitchell MS, Wade ME, Deconti RC, et al. Immunosuppressive effects of cytosine arabinoside and methotrexate in man. Ann Int Med 1969; 70: 535–547.PubMedGoogle Scholar
  377. 377.
    Miwa H, Orita K. Immunotherapy of gastrointestinal cancer patients with levamisole. Acta Med Okayama 1979;33:29–42.PubMedGoogle Scholar
  378. 378.
    Miwa H, Orita K. Cancer immunotherapy with levamisole. Acta Med Okayama 1978; 32: 239–245.PubMedGoogle Scholar
  379. 379.
    Miwa H, Orita K. Reactivating effect of levamisole on cell-mediated immunity in gastrointestinal cancer patients. Acta Med Okayama 1977; 31: 325–329.PubMedGoogle Scholar
  380. 380.
    Modini C, Ziparo V, Cicconetti F, et al. Role of delayed cutaneous hypersensitivity reaction in classifying patients with bronchial carcinoma. Tumori 1985; 71: 277–281.PubMedGoogle Scholar
  381. 381.
    Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 6; 352–358.PubMedGoogle Scholar
  382. 382.
    Moertel CG, Ritts RE, O’Connell MJ, Silvers A. Nonspecific immune determinants in the patient with unresectable gastrointestinal carcinoma. Cancer 1979; 43: 1483–1492.PubMedGoogle Scholar
  383. 383.
    Monson JR, Ramsden C, Guillou PJ. Decreased interleukin- 2 production in patients with gastrointestinal cancer. Br J Surg 1986; 73: 6; 483–486.PubMedGoogle Scholar
  384. 384.
    Monte JE, Bukowski RM, James RE, et al. A critical review of immunotherapy of disseminated renal adenocarcinoma. J Surg Oncol 1982; 21:5–8.Google Scholar
  385. 385.
    Morales A, Eidinger D. Immune reactivity in renal cancer. J Urol 1976; 115: 510–513.PubMedGoogle Scholar
  386. 386.
    Morin A, Ballet J, Touraine J, Hadder JW. Current status of isoprinosine. In: Serrou BRosenfeld CDaniels JCSaunders JP, eds. Current concepts in human immunology and cancer immunomodulation. Amsterdam: Elsevier Biomedical, 1982:479–489.Google Scholar
  387. 387.
    Morton DL, Eilber FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970; 68: 158–164.PubMedGoogle Scholar
  388. 388.
    Mukherji B, Guha A, Loomis R, Ergin MT. Cell-mediated amplification and down regulation of cytotoxic immune response against autologous human cancer. J Immunol 1987;138:1987–1991.PubMedGoogle Scholar
  389. 389.
    Mukhopadhyaya R, Advani SH, Gangal SG. Functional evaluation of T-lymphocytes from peripheral blood and spleens in Hodgkin’s disease. Br J Cancer 1987; 56: 800–802.PubMedGoogle Scholar
  390. 390.
    Munster AM. Post-traumatic immunosuppression is due to activation of suppressor T-cells. Lancet 1976; 1: 1329.PubMedGoogle Scholar
  391. 391.
    Munzarova M, Mechl Z, Kovarik J, Kolcova V Skin tests with autologous cholesteryl hemisuccinate-treated tumor cells, DNCB and PPD and their relationship to prognosis in malignant melanoma patients. Neoplasma 1988; 35: 2, 229–234.PubMedGoogle Scholar
  392. 392.
    Murphy RM, Colton CK, Yarmush ML. Staphylococcal protein A adsorption in neoplastic disease: Analysis of physiochemical aspects. Mol Biother 1989; 1:4,186–207.PubMedGoogle Scholar
  393. 393.
    Murray JL, Kollmorgen GM. Inhibition of lymphocyte response by prostaglandin-producing suppressor cells in patients with melanoma. J Clin Immunol 1983; 3: 268–276.PubMedGoogle Scholar
  394. 394.
    Murray JL, Reuben JM, Smith TL, et al. A pilot clinical trial of the toxicity and immunorestorative effects of T-cell reconstituting factor (SR 270258) in immunosuppressed cancer patients. J Biol Response Mod 1987; 6: 1, 56–68.PubMedGoogle Scholar
  395. 395.
    Najjar VA. Biochemistry and physiology of tuftsin - Thr- Lys-Pro-Arg. In: Sbarra SStrauss R, eds. The reticuloendothelial system. New York: Plenum Press, 1980: 45–71.Google Scholar
  396. 396.
    Nathanson SD, Zamfirescu PL, Portaro JK, et al. Acute effects of orally administered levamisole on random monocyte motility and chemotaxis in man. J Natl Cancer Inst 1978; 61: 301–306.PubMedGoogle Scholar
  397. 397.
    Nemoto T, Han T, Minowada J, et al. Cell-mediated immune status of breast cancer patients: evaluation by skin tests, lymphocyte stimulation and counts of rosetteforming cells. J Natl Cancer Inst 1974; 53: 641–645.PubMedGoogle Scholar
  398. 398.
    Niimoto M, Hattori T, Ito I, et al. Levamisole as postoperative adjuvant immunochemotherapy for gastric cancer. A randomized controlled study of the MMC + Tegafur regimen with or without levamisole. Report I. Cancer Immunol Immunother 1984; 18: 13–18.PubMedGoogle Scholar
  399. 399.
    Noda T, Asano M, Yoshie O, et al. Interferon-y induction of human peripheral blood mononuclear cells by OK-432, a killed preparation of Streptococcus pyogenes. Microbiol Immunol 1985; 30: 81–88.Google Scholar
  400. 400.
    Noma T, Yoshimura N, Yata J. Depressed lymphocyte functions of cancer patients and their correlation by bestatin (product of Streptomyces olivereticuli). In: Serrou SRosenfeld CDaniels JCSaunders JP, eds. Current concepts in human immunology and cancer immunomodulation. Amsterdam: Elsevier Biomedical, 1982:611–616.Google Scholar
  401. 401.
    Nordman E, Saarimaa H, Tolvanen A. The influence of 5- fluorouracil on cellular and humoral immunity in cancer patients. Cancer 1978; 41: 64–69.PubMedGoogle Scholar
  402. 402.
    Nordman E, Tolvanen A. Effects of irradiation of the immune function in patients with mammary, pulmonary or head and neck carcinoma. Acta Radiol Oncol Radiat Phys Biol 1978; 17:3–9.PubMedGoogle Scholar
  403. 403.
    Norris RW, Byrom NA, Nagvekar NM, et al. Thymostimulin plus surgery in the treatment of primary truncal malignant melanoma: Preliminary results of a U.K. multicentre clinical trial. In: Byrom NAHobbs JR, eds Thymic factor therapy. New York: Raven Press, 1984: 341–348.Google Scholar
  404. 404.
    Oka S. A review of clinical studies of bestatin. Recent results. Cancer Res 1980; 75: 126–132.Google Scholar
  405. 405.
    Olivari A, Pradier R, Feierstein H, et al. Cell-mediated immune response in head and neck cancer patients. J Surg Oncol 1976; 8:287–294.PubMedGoogle Scholar
  406. 406.
    Olivari AJ, Glait HM, Guardo A, et al. Levamisole in squamous-cell carcinoma of the head and neck. Cancer Treat Rep 1979; 63: 983–990.PubMedGoogle Scholar
  407. 407.
    Onsrud M. Whole pelvic irradiation in stage I endometrial carcinoma: changes in numbers and reactivities of some blood lymphocyte subpopulations. Gynecol Oncol 1982; 13:283–292.PubMedGoogle Scholar
  408. 408.
    Orita K, Miwa H, Fukuda H, et al. Preoperative cellmediated immune status of gastric cancer patients. Cancer 1976; 38: 2343–2348.PubMedGoogle Scholar
  409. 409.
    Osband M, Shen Y, Schlesinger M, et al. Successful tumor immunotherapy with cimetidine in mice. Lancet 1981; 1: 636–638.PubMedGoogle Scholar
  410. 410.
    Oshimi K, Kano S, Takaku F, Okumura K. Augmentation of mouse natural killer cell activity by a streptococcal preparation OK-432. J Natl Cancer Inst 1980; 65: 1265–1269.PubMedGoogle Scholar
  411. 411.
    Ota K, Kurita S, Yamada K, et al. Immunotherapy with bestatin for acute non-lymphocytic leukemia in adults. Cancer Immunol Immunother 1986; 23: 1; 5–10.PubMedGoogle Scholar
  412. 412.
    Ozer H. Effects of alkylating agents on immunoregulatory mechanisms. In: Mihich ESakurai Y, eds. Biological responses in cancer, vol 3: immunomodulation by anticancer drugs. New York: Plenum Press, 1985: 95–129.Google Scholar
  413. 413.
    Paavonen T, Anderson LC, Adlercrentz H. Estradiol enhances human B-cell maturation via inhibition of suppressor T-cells in pokeweed mitogen-stimulated cultures. J Exp Med 1981; 154: 1935–1945.PubMedGoogle Scholar
  414. 414.
    Padmanabhan TK, Balaram P, Vasudevan DM. Role of levamisole immunotherapy as an adjuvant to radiotherapy in oral cancer. I.A three-year clinical follow-up. Neoplasma 1987; 34: 5,627–632.PubMedGoogle Scholar
  415. 415.
    Paik YK, Kimura L, Yanagihora E, et al. Inhibition of the phytohemagglutinin stimulation of leukocytes by Creactive protein. J Reticuloendothel Soc 1972; 11:420.Google Scholar
  416. 416.
    Papatestas AE, Kark AE. Peripheral lymphocyte counts in breast carcinoma: an index of immune competence. Cancer 1918; 34: 2014–2017.Google Scholar
  417. 417.
    Papenhausen PR, Kukwa A, Croft CB, et al. Cellular immunity in patients with epidermoid cancer of the head and neck. Laryngoscope 1979; 89: 538–549.PubMedGoogle Scholar
  418. 418.
    Park SK, Brody JL, Wallace HA, Blakemore WS. Immunosuppressive effect of surgery. Lancet 1971; 1: 53–55.PubMedGoogle Scholar
  419. 419.
    Parkinson DR, Cano PO, Jerry LM, et al. Complications of cancer immunotherapy with levamisole. Lancet 1977; i: 1129-1132.Google Scholar
  420. 420.
    Passwell J, Lavanon M, Davidsohn J, Ramot B. Monocyte PG E2 secretion in Hodgkin’s disease and its relation to decreased cellular immunity. Clin Exp Immunol 1983; 51: 61–68.PubMedGoogle Scholar
  421. 421.
    Paterson AHG, Natting M, Takata L, et al. Chemoimmunotherapy with levamisole in metastatic breast carcinoma: a controlled clinical trial. Cancer Clin Trials 1980; 3:5–10.PubMedGoogle Scholar
  422. 422.
    Patt YZ, Hersh EM, Reuben J, et al. A phase-I study of intravenous azimexon therapy in human cancer. J Biol Response Mod 1986; 5:4; 313–318.PubMedGoogle Scholar
  423. 423.
    Pauwels R, Van derStraeter M. Delayed hypersensitivity in patients with bronchial carcinoma. Scand J Resp 1975; 56: 160–164.Google Scholar
  424. 424.
    Pavlovsky S, Muriel FS, Garay G, et al. Chemoimmunotherapy with levamisole in acute lymphoblastic leukemia. Cancer 1981;A8: 1500–1507.Google Scholar
  425. 425.
    Pavlovsky S, Garay G, Sackman MF, Svarch E. Levamisole therapy during maintenance of remission in patients with acute lymphoblastic leukemia. In: Terry WD, ed. Proceedings of Second International Conference on Immunotherapy of Cancer. Amsterdam: Elsevier/ North-Holland, 1980: 47–54.Google Scholar
  426. 426.
    Payne JE, Meyer JH, Macpherson JG, et al. The value of lymphocyte transformation in carcinoma of the colon and rectum. Surg Gynecol Obstet 1980; 150: 687–693.PubMedGoogle Scholar
  427. 427.
    Penn I. Tumors of the immunocompromised patient. Annu Rev Med 1988; 39:63–73.PubMedGoogle Scholar
  428. 428.
    Penn I. Occurrence of cancer in immune deficiency. Cancer 1974; 34:858–866.PubMedGoogle Scholar
  429. 429.
    Perez CA, Bauer M, Emami BN, et al. Thoracic irradiation with or without levamisole (NSC #177023) in unresectable non-small-cell carcinoma of the lung: A phase III randomized trial of the RTOG. Int J Radiation Oncology Biol Phys 1988; 15: 6,1337–1346.Google Scholar
  430. 430.
    Petrini B, Wasserman J, Blomgren H, Rotstein S. T-helper/ suppressor ratios in chemotherapy and radiotherapy. Clin Exp Immunol 1983; 53: 255–256.PubMedGoogle Scholar
  431. 431.
    Petrini B, Wasserman J, Glas U, Blomgren H. T-lymphocyte subpopulations in blood following radiation therapy for breast cancer. Eur J Cancer Clin Oncol 1982; 18: 921–924.PubMedGoogle Scholar
  432. 432.
    Petrini B, Wasserman J, Biberfeld G, et al. The effect of in vitro irradiation on PHA-mediated cytotoxicity and lymphocytes with receptors for the Fc pat of Ig. J Clin Lab Immunol 1979;2:333–336.PubMedGoogle Scholar
  433. 433.
    Pierri I, Cordone G, Rogna S, et al. T-lymphocyte phenotype and functions in patients with head and neck cancer. Laryngoscope 1985; 95: 577–581.PubMedGoogle Scholar
  434. 434.
    Pines A. BCG plus levamisole following irradiation of advanced squamous bronchial carcinoma. Int J Radiation Oncology Biol Phys 1980; 6: 1041–1042.Google Scholar
  435. 435.
    Pinsky CM, El-Domeiri A, Caron AA, et al. Delayed hypersensitivity reactions in patients with cancer. In: Mathe G, Weiner R, eds. Recent results in cancer research, pp. 37-41.Google Scholar
  436. 436.
    Pinsky CM, Wanebo H, Mike V, Oettgen H. Delayed cutaneous hypersensitivity reactions and prognosis in patients with cancer. Ann NY Acad Sci 1976; 276: 407–410.PubMedGoogle Scholar
  437. 437.
    Pitchenik AE, Guffee J, Stein-Streilein J. Lung natural killer and interleukin-2 activity in lung cancer. A pulmonary compartment of augmented natural killer activity occurs in patients with bronchogenic carcinoma. Am Rev RespirDis 1987; 136: 6,1327–1332.PubMedGoogle Scholar
  438. 438.
    Plesnicar S. Immunoglobulins in carcinoma of the uterine cervix. Acta Radiol 1972; 11: 37–47.Google Scholar
  439. 439.
    Pompidou A, Soubrane C, Cour V, et al. Immunological effects of isoprinosine as a pulse immunotherapy in melanoma and ARC patients. Cancer Detect Prev Suppl 1987;1:457–462.PubMedGoogle Scholar
  440. 440.
    Posner MR, Reinherz E, Lane H, et al. Circulating lymphocyte populations in Hodgkin’s disease after mantle and para-aortic irradiation. Blood 1983; 61: 705–708.PubMedGoogle Scholar
  441. 441.
    Powles TJ, Dady DJ, Williams J, et al. Use of inhibitor of prostaglandin synthesis and patients with breast cancer. In: Sammuelsson BRamwel PWPaoletti R, eds. Advances in prostaglandin and thromboxane research, vol 6. New York: Raven Press, 1980: 511–516.Google Scholar
  442. 442.
    Prehn RT, Prehn LM. The flip side of tumor immunity. Arch Surg 1989; 124: 102–106.PubMedGoogle Scholar
  443. 443.
    Prehn RT, Prehn LM. The autoimmune nature of cancer. Cancer Res February 15,1987: 927–932.Google Scholar
  444. 444.
    Pritchard DJ, Ritts RE Jr, Taylor WF, Miller GC.A prospective study of immune responsiveness in humans. I. Assessment of initial pretreatment status with stage of disease. Cancer 1978; 41: 2165–2173.PubMedGoogle Scholar
  445. 445.
    Pross HF, Baines MG. Spontaneous human lymphocytemediated cytotoxicity against tumor target cells: I. The effect of malignant disease. Int J Cancer 1976; 18: 593–604.PubMedGoogle Scholar
  446. 446.
    Pui C-H, Ip SH, Kung P, et al. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin’s lymphoma. Blood 1987; 70: 3; 624–628.PubMedGoogle Scholar
  447. 447.
    Pulay TA, Csomor S. Effect of levamisole treatment on immunological parameters and the early course of cervical cancer. Neoplasia 1980; 29: 81–86.Google Scholar
  448. 448.
    Quirt I, Shelley W, Bodurtha A, et al. Adjuvant levamisole improves survival and disease-free survival in patients with poor prognostics with malignant melanoma. (Abstr.) Proc ASCO 1986; 5: 130.Google Scholar
  449. 449.
    Raben M, Walch N, Galili U, Schlesinger M. The effect of radiation therapy on lymphocyte subpopulations in cancer patients. Cancer 1976; 37: 1417–1421.PubMedGoogle Scholar
  450. 450.
    Ramot B, Biniaminov M, Shoham C, Rosenthal E. The effect of levamisole on E-rosette-forming cells in vivo and in vitro in Hodgkin’s disease patients. N Engl Med 1976; 194:809–811.Google Scholar
  451. 451.
    Ramot B, Rosenthal E, Biniaminov M, Ben-Bassat I. Effect of levamisole, thymic humoral factor, and indomethacin on E-rosette formation of lymphocytes in Hodgkin’s disease. IsrJMedSci 1981; 17: 232–235.PubMedGoogle Scholar
  452. 452.
    Rand RJ, Jenkins DM, Bulmer R. T and B lymphocyte subpopulations in pre-invasive and invasive carcinoma of the cervix. Clin Exp Immunol 1977; 30:421–428.PubMedGoogle Scholar
  453. 453.
    Rangel DM, Golub SH, Morton DL. Demonstration of lymphocyte blastogenesis-inhibiting factors in sera of melanoma patients. Surgery 1977; 82: 224–232.PubMedGoogle Scholar
  454. 454.
    Rapson NT, Cornbleet MA, Chessells JM, Hardisity RM. Immunosuppression and serious infections in children with acute lymphoblastic leukemia: a comparison of the three chemotherapy regimens. Br J Hematol 1980; 45:41– 52.Google Scholar
  455. 455.
    Ravikumar T, Steele G, Rodrick M, et al. Effects of tumor growth on interleukins and circulating immune complexes. Cancer 1984;53:1373–1378.PubMedGoogle Scholar
  456. 456.
    Reed DM. On the pathological changes in Hodgkin’s disease with special references to its relation to tuberculosis. Johns Hopkins Hosp Rep 1902: 10: 133–198.Google Scholar
  457. 457.
    Rees JC, Rossio JL, Wilson HG, et al. Cellular immunity in neoplasia. Antigen and mitogen responses in patients with bronchogenic carcinoma. Cancer 1975; 36: 2010–2015.PubMedGoogle Scholar
  458. 458.
    Remacle-Bonnet MM, Rommier GJ, Luc C, et al. Nonspecific suppressive and cytostatic activities mediated by human colonic carcinoma tissue or cultured cell extract. J Immunol 1978; 121:44–52.PubMedGoogle Scholar
  459. 459.
    Renoux G, Renoux M. DTC.A summary of current status. In: Serrou BRosenfeld CDaniels JCSaunder JP, eds. Current concepts in human immunology and cancer immunomodulation. Amsterdam: Elsevier Biomedical 1982: 575–584.Google Scholar
  460. 460.
    Renoux G, Renoux M. Effect immunostimulant d’un imidothiazole dans 1’immunization des souris contre l’infecction par Brucella abortus. CR Acad Sci (Paris) 1971; 272; 349–350.Google Scholar
  461. 461.
    Ress JC, Rossio HL, Wilson HE, et al. Cellular immunity in neoplasia. Antigen and mitogen response in patients with bronchogenic carcinoma. Cancer 1975; 36: 2010–2015.Google Scholar
  462. 462.
    Retsas S, Thomas C, Hobbs JR. The effect of vindesine therapy on the in vitro immune response of patients with advanced malignant melanoma. Clin Oncol 1981; 7: 33–37.PubMedGoogle Scholar
  463. 463.
    Richtsmeier WJ, Eisele D. In vivo anergy reversal with cimetidine in patients with cancer. Arch Otolaryngol Head Neck Surg 1986; 112: 10; 1074–1077.PubMedGoogle Scholar
  464. 464.
    Riddle PR. Disturbed immune reactions following surgery.BRJ Surg 1967; 54: 882–886.Google Scholar
  465. 465.
    Riddle PR, Berenbaum MC. Postoperative depression of the lymphocyte response to phytohemagglutinin. Lancet 1967; 1:746–748.PubMedGoogle Scholar
  466. 466.
    Rijswijk REN, Sybesma JPH, Kater L. A prospective study of the changes in the immune status before, during and after multiple agent chemotherapy for Hodgkin’s disease. Cancer 1983; 51: 637–644.PubMedGoogle Scholar
  467. 467.
    Rijswijk REN, Sybesma JPH, Kater L. A prospective study of the changes in immune status following radiotherapy for Hodgkin’s disease. Cancer 1984; 53: 62–69.PubMedGoogle Scholar
  468. 468.
    Roberts MM. Lymphocyte transformation in breast cancer. Br J Surg 1970; 57: 381.PubMedGoogle Scholar
  469. 469.
    Robinson BW. Asbestos and cancer: human natural killer cell activity is suppressed by asbestos fibers but can be restored by recombinant interleukin-2. Am Rev Respir Dis 1978; 139:4, 897–901.Google Scholar
  470. 470.
    Rojas AF, Feirstan JN, Glait HM, Olivari AJ. Levamisole action in breast cancer. In: Terry WDWindhorst D, eds. Immunotherapy of cancer: present status on trials in man. New York: Raven Press, 1978: 635–646.Google Scholar
  471. 471.
    Romagnani S, Maggi E, DelPrete G, et al. Short- and long-term effects of radiation on T-cell subsets in peripheral blood of patients with Hodgkin’s disease. Cancer 1980; 46: 2590–2595.PubMedGoogle Scholar
  472. 472.
    Romagnani S, Ferrini PLR, Ricci M. The immune derangement in Hodgkin’s disease. Semin Oncol 1985; 22:41–55.Google Scholar
  473. 473.
    Rosenberg SA, Seipp CA, White DE, Wesley R. Perioperative blood transfusions are associated with increased rates of recurrence and decreased survival in patients with high-grade soft-tissue sarcomas of the extremities. J Clin Oncol 1985; 3: 5; 698–709.PubMedGoogle Scholar
  474. 474.
    Roses DF, Campion JF, Harris MN, Gumport SL. Malignant melanoma. Delayed hypersensitivity skin testing. Arch Surg 1979; 114: 35–38.PubMedGoogle Scholar
  475. 475.
    Rossen RD, Morgan AC. Blockage of the humoral immune response: Immune complexes in cancer. Cancer Immunol 1980; 210-280.Google Scholar
  476. 476.
    Roth JA, Osborne BA, Ames RS. Immunoregulatory factors derived from human tumors. II. Partial purification and further immunobiochemical characterization of a human sarcoma-derived immunosuppressive factor expressing HLA-DR and immunoglobulin-related determinants. J Immunol 1983; 130: 303–308.PubMedGoogle Scholar
  477. 477.
    Roth JA, Golub SH, Grimm EA, et al. Effects of operation on immune response in cancer patients: Sequential evaluation of in vitro lymphocyte function. Surgery 1976; 79:47–51.Google Scholar
  478. 478.
    Rotstein S, Blomgren H, Petrini B, et al. Long-term effects on the immune system following local radiation for breast cancer. I. Cellular composition of the peripheral blood lymphocyte population. Int J Radiat Oncol Biol Phys 1985; 11:921–925.PubMedGoogle Scholar
  479. 479.
    Rotstein S, Blomgren H, vonStedingk LV, et al. Longterm effects on the immune system following local irradiation for breast cancer. Pokeweed mitogen-induced immunoglobulin secretion by blood lymphocytes and serum immunoglobulin levels. Eur J Surg Oncol 1985; 11: 137–141.PubMedGoogle Scholar
  480. 480.
    Rotstein S, Blomgren H, Nilsson B, et al. Prognostic value of various immunological tests in breast cancer patients treated with adjuvant postoperative chemotherapy. Chemotherapy 1984; 3: 227–231.Google Scholar
  481. 481.
    Rotstein S, Blomgren H, Petrini, et al. Blood lymphocyte counts with subset analysis in operable breast cancer. Cancer 1985;56: 1413–1419.PubMedGoogle Scholar
  482. 482.
    Ruco LP, Procopio A, Valtieri M, et al. Increased monocyte phagocytosis and decreased lymphocyte mitogen reactivity in colorectal cancer patients. Appl Pathol 1983; 1: 149–156.PubMedGoogle Scholar
  483. 483.
    Ryan RE Jr, Neel HB, Ritts RE. Correlation of preoperative immunologic test results with recurrence in patients with head and neck cancer. Otolaryngol Head Neck Surg 1980; 88:58–63.PubMedGoogle Scholar
  484. 484.
    Saijo N, Shimizu E, Irimajiri N, et al. Analysis of NK activity and ADCC in healthy volunteers and in patients with primary lung carcinoma and metastatic pulmonary tumors. J Cancer Reg Clin Oncol 1982; 102: 195–214.Google Scholar
  485. 485.
    Saijo N, Shimizu E, Shibuya M, et al. Effect of chemotherapy on natural killer (NK) activity and antibody- dependent cell-mediated cytotoxicity in carcinoma of the lung. Br J Cancer 1982; 46: 180–189.PubMedGoogle Scholar
  486. 486.
    Saito M, Ebina T, Koi M, et al. Induction of interferongamma in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes. Cell Immunol 1982; 68: 187–192.PubMedGoogle Scholar
  487. 487.
    Salmon SE, Hunt A, Bonnet JD, et al. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: A Southwest Oncology Group study. J Clin Oncol 1983; 1:453–461.PubMedGoogle Scholar
  488. 488.
    Sample WF, Gertner HR, Chretien PB. Inhibition of phytohemagglutinin-induced in vitro lymphocyte transformation by serum from patients with carcinoma. J Natl Cancer Inst 1971; 46: 1291–1297.PubMedGoogle Scholar
  489. 489.
    Santos GW, Owens AH, Sensenbrenner LL. Effects of selected cytotoxic agents on antibody production in man: A preliminary report. Ann NY Acad Sci 1964; 114: 404–423.PubMedGoogle Scholar
  490. 490.
    Santos LB, Yamada FT, Scheinberg MA. Monocyte and lymphocyte interaction in patients with advanced cancer. Evidence for deficient IL-1 production. Cancer 1985; 56: 1553–1558.PubMedGoogle Scholar
  491. 491.
    Sarin PS, San DK, Thornton AH, et al. Neutralization of HTLV-III/LAV replication by antiserum to thymosinalpha- one. Science 1986; 232: 1135–1137.PubMedGoogle Scholar
  492. 492.
    Scambia G, Panici PB, Mancuso S, et al. Effects of antiestrogen and progestin on immune functions in breast cancer patients. Cancer 1988; 61: 2214–2218.PubMedGoogle Scholar
  493. 493.
    Schantz SP, Romsdahl MM, Babcock GF, et al. The effect of surgery on natural killer cell activity in head and neck cancer patients: In vitro reversal of a postoperatively suppressed immunosurveillance system. Laryngoscope 1985;95:588–594.PubMedGoogle Scholar
  494. 494.
    Schantz SP, Savage HE, Racz T, et al. Immunologic determinants of head and neck cancer response to induction chemotherapy. J Clin Oncol 1989; 7: 7, 857–864.PubMedGoogle Scholar
  495. 495.
    Schlechter GP, Wahl LM, Oppenheim JJ. Suppressor monocytes in human disease: a review. Adv Exp Med Biol 1979; 121B, 283–298.Google Scholar
  496. 496.
    Schechter GP, Soehlen F. Monocyte-mediated inhibition of lymphocyte blastogenesis in Hodgkin’s disease. Blood 1978;52:261–271.PubMedGoogle Scholar
  497. 497.
    Scher HI, Shank B, Chapman R, et al. Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer. Cancer Res 1988; 48: 1663–1670.PubMedGoogle Scholar
  498. 498.
    Schindler L, Leroux M, Zimmerman GF, et al. Reversal of defective lymphoproliferation in postoperative patients with colon cancer. J Cancer Res Clin Oncol 1987; 113:2, 166–170.PubMedGoogle Scholar
  499. 499.
    Schlelhammer PF, Bracken RB, Bean M, et al. Immune evaluator with skin testing. A study of testicular, prostatic, and bladder neoplasms. Cancer 1976; 38: 149–156.Google Scholar
  500. 500.
    Schlumberger HD. BAYI 7433: a synthetic polymer with antitumor activity. In: Hersh EMCirigos MAMastrangeloMJ, eds. Augmenting agents in cancer therapy. New York: Raven Press, 1981: 373–390.Google Scholar
  501. 501.
    Schulof RS, Lloyf MJ, Cleary PA, et al. A randomized trial to evaluate the immunorestorative properties of thymosinalpha- one in patients with lung cancer. J Biol Response Mod 1985; 4: 147–158.PubMedGoogle Scholar
  502. 502.
    Schulof RS, Bockman RS, Garofalo JA, et al. Multivariate analysis of T-cell functional defects and circulating serum factors in Hodgkin’s disease. Cancer 1981; 48: 964–973.PubMedGoogle Scholar
  503. 503.
    Schulof RS, Michitsch RW, Livingston PO, Gupta S. Monocyte-mediated suppression on lymphocyte cytotoxic activity for cultured autologous melanoma cells. Cell Immunol 1981; 57: 529–532.PubMedGoogle Scholar
  504. 504.
    Schulof RS, Chorba TC, Cleary PA, et al. T-cell abnormalities after mediastinal irradiation for lung cancer. The in vitro influence of synthetic thymosin alpha-1. Cancer 1985;55:974–983.Google Scholar
  505. 505.
    Schulof RS. Thymic peptide hormones: Basic properties and clinical applications in cancer. CRC Critical Rev Oncol Hematol 1985; 3: 309–376.Google Scholar
  506. 506.
    Schulof RS, Lee BJ, Lacher MJ, et al. Concanavalin-Ainduced suppressor cell activity in Hodgkin’s disease. Clin Immunol Immunopathol 1980; 16:454–462.PubMedGoogle Scholar
  507. 507.
    Schulof RS, Lloyd MJ, Ueno WM, et al. Phase II trial of thymosin fraction 5 in advanced renal cancer. J Biol Response Mod 1984; 3:151–159.PubMedGoogle Scholar
  508. 508.
    Schulof RS, Lacher M J, Gupta S. Abnormal phytohemagglutinin- induced T-cell proliferative responses in Hodgkin’s disease. Blood 1981; 57: 607–613.PubMedGoogle Scholar
  509. 509.
    Sears HF, Simon R, Rosenberg SA. Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy. Cancer Treat Rep 1980; 64: 589–597.PubMedGoogle Scholar
  510. 510.
    Seder RH, Katz AE, Keggins J J, et al. Plasma exchange in six patients with advanced cancers of the head and neck. J Clin Apheresis 1985; 2: 238–249.PubMedGoogle Scholar
  511. 511.
    Seder RH, Katz AE, Keggins JJ, et al. Plasma exchange in six patients with advanced cancers of the head and neck. J Clin Apheresis 1985; 2:238–249.PubMedGoogle Scholar
  512. 512.
    Seder RH, Vaughn CW, Oh S-K, et al. Tumor regression and temporary restoration of immune response after plasmapheresis in a patient with recurrent oral cancer. Cancer 1987; 60: 318–325.PubMedGoogle Scholar
  513. 513.
    Sedman PC, Ramsden CW, Brennan TG, et al. Effects of low-dose perioperative interferon on the surgically induced suppression of antitumor immune response. Br J Surg 1988; 75: 976–981.PubMedGoogle Scholar
  514. 514.
    Sen L, Borella L. Expression of cell surface markers on Tand B-lymphocytes after long-term chemotherapy of acute leukemia. Cell Immunol 1973; 9: 84–95.PubMedGoogle Scholar
  515. 515.
    Serdengecti S, Buyukunal E, Molinas N, et al. Overall survival results of non-small cell lung cancer patients: Chemotherapy alone versus chemotherapy with combined immunomodulation. Chemioterapia 1988; 7: 2; 122–126.PubMedGoogle Scholar
  516. 516.
    Sertoli MR, Guarneri D, Rubagotti A, et al. Adjuvant immunochemotherapy in colorectal cancer. Dukes C. Oncology 1987; 44: 2; 78–81.Google Scholar
  517. 517.
    Shafir M, Bekesi JG, Papatestas A, et al. Preoperative and postoperative immunological evaluation of patients with colorectal cancer. Cancer 1980; 46: 700–705.PubMedGoogle Scholar
  518. 518.
    Shank B, Scher H, Hilaris BS, et al. Increased survival with high-dose multified radiotherapy and intensive chemotherapy in limited small cell carcinoma of the lung. Cancer 1985; 56: 2771–2778.PubMedGoogle Scholar
  519. 519.
    Shiraki S, Mori H, Kadomoto N, et al. Adjuvant immunotherapy of carcinoma colli with levamisole. Prevention of immunological depression following surgical therapy and radiotherapy. Int J Immunopharmacol 1982; 4: 73–80.PubMedGoogle Scholar
  520. 520.
    Shoham J, Theodore E, Brenner HJ, et al. Enhancement of the immune system of chemotherapy-treated cancer patients by simultaneous treatment with thymic extract, TP-1. Cancer Immunol Immunother 1980; 9: 173–180.Google Scholar
  521. 521.
    Shukla HS, Hughes LE, Whitehead RH, Newcombe RG. Long-term (5-11 years) follow-up of general immune competence in breast cancer. I. Pretreatment levels with reference to micrometastasis. Cancer Immunol Immunother 1986;21 :1–5.PubMedGoogle Scholar
  522. 522.
    Shukla HS, Hughes LE, Whitehead RH, Newcomb RG. Long-term follow-up of general immune competence in breast cancer. II. Sequential pre- and post-treatment levels: A 10-year study. Cancer Immunol Immunother 1986;21:6–11.PubMedGoogle Scholar
  523. 523.
    Sibbit WL, Bankhurst AD, Williams RC. Studies of cell subpopulations mediating mitogen hyporesponsiveness in patients with Hodgkin’s disease. J Clin Invest 1978; 61: 55–63.Google Scholar
  524. 524.
    Silverman NA, Alexander JC, Potvin C, Chretien PB. In vitro lymphocyte reactivity and T-cell levels in patients with melanoma: correlations with clinical and pathological stage. Surgery 1976; 79: 332–339.PubMedGoogle Scholar
  525. 525.
    Silverman NA, Alexander JC, Potvin C, Chretien PB. Effect of nonthymic irradiation on cellular immunocompetence. Surg Forum 1975; 26: 345–346.PubMedGoogle Scholar
  526. 526.
    Sinclair T, Ezdinli EZ, Boonlayangoor P, et al. Rosette and blastogenesis inhibition by plasma from Hodgkin’s disease and other malignancies. Positive correlation in stage I and II Hodgkin’s disease. Cancer 1983; 51: 238–244.PubMedGoogle Scholar
  527. 527.
    Slade MS, Simmons RL, Yunis E, Greenberg LJ. Immunodepression after major surgery in normal patients. Surgery 1975; 78: 363–372.PubMedGoogle Scholar
  528. 528.
    Slater JM, Ngo E, Lau BHS. Effect of therapeutic irradiation on the immune response. Am J Roentgenol Radium TherNucl Med 1976; 126: 313–320.Google Scholar
  529. 529.
    Smalley RV, Talmadge J, Oldham RK, Thurman GB. The thymosins: Preclinical and clinical studies with fraction V and alpha-1. Cancer Treat Rev 1984; 11: 69–84.PubMedGoogle Scholar
  530. 530.
    Smith RB, Dekernion J, Baron B, et al. Levamisole in the treatment of non-invasive and invasive bladder cancer: a preliminary report. J Urol 1978; 119: 347–349.PubMedGoogle Scholar
  531. 531.
    Snyderman R, Siegler HF, Meadew R. Abnormalities of monocyte chemotaxis in patients with melanoma: Effects of immunotherapy and tumor removal. J Natl Cancer Inst 1977;58:37–41.PubMedGoogle Scholar
  532. 532.
    Sokal JE, Aungst CW. Response to BCG vaccination and survival in advanced Hodgkin’s disease. Cancer 1969; 24: 128–134.PubMedGoogle Scholar
  533. 533.
    Soto A, Hall T, Reed S. Trial of antiviral action of isoprinosine against rhinovirus infection of volunteers. Antimicrob Agent Chemother 1973; 3: 332–334.Google Scholar
  534. 534.
    Soulillou JP, Douillard JU, Vie H, et al. Defects in lectininduced interleukin-2 (IL-2) production by peripheral blood lymphocytes of patients with Hodgkin’s disease. Eur J Cancer Clin Oncol 1985; 21: 935.PubMedGoogle Scholar
  535. 535.
    Spitler LE, Sagebiel R. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. N Engl J Med 1980; 303: 1143–1147.PubMedGoogle Scholar
  536. 536.
    Spreafico F, Vecchi A. The imunomodulatory activity of certain cancer chemotherapeutic agents. In: Mihich ESakurai Y, eds. Biological responses in cancer, vol. 3: immunomodulation by anti-cancer drugs. New York: Plenum Press, 1985: 131–149.Google Scholar
  537. 537.
    Steele G, Wang BS, Mannick JA. Immune RNA and transfer factor. In: Mihich E, ed. Immunological approaches to cancer therapeutics. New York: Wiley, 1982:257–276.Google Scholar
  538. 538.
    Stefani S, Kerman R, Abbate J. Serial studies of immunocompetence in head and neck cancer patients undergoing radiation therapy. Am J Roentgenol Radium Ther Nucl Med 1976; 126: 880–886.Google Scholar
  539. 539.
    Stefano S, Kerman R, Abbate J. Serial studies of immunocompetence in head and neck cancer patients undergoing radiation therapy. Am J Roentgenol 1976; 126: 880– 886.Google Scholar
  540. 540.
    Stein JA, Adler A, Efraim SB, Maor M. Immunocompetence, immunosuppression and human breast cancer. Cancer 1976; 38: 1171–1187.PubMedGoogle Scholar
  541. 541.
    Stephens EJW, Wood HF, Mason B. Levamisole as adjuvant to cyclic chemotherapy in end-stage mammary carcinoma. Recent Results Cancer Res 1978; 68: 139–145.PubMedGoogle Scholar
  542. 542.
    Stratton JA, Byfield PE, Byfield JE, et al. A comparison of the acute effects of radiation therapy, including or excluding the thymus, or the lymphocyte subpopulations of cancer patients. J Clin Invest 1975; 56: 88–97.PubMedGoogle Scholar
  543. 543.
    Stratton JA, Fast PE, Weintraub I. Recovery of lymphocyte function after radiation therapy for cancer in relationship to prognosis. J Clin Lab Immunol 1982; 7: 147–153.PubMedGoogle Scholar
  544. 544.
    Strender LE, Blomgren H, Wasserman J, et al. Influence of adjuvant radiation therapy in breast cancer on PWMinduced Ig secretion by blood lymphocytes in vitro. Anticancer Res 1983; 3:41–45.PubMedGoogle Scholar
  545. 545.
    Strender LE, Blomgren H, Petrini B, et al. Immunologic monitoring in breast cancer patients receiving postoperative adjuvant chemotherapy. Cancer 1981; 48: 1996–2002.PubMedGoogle Scholar
  546. 546.
    Sugden PJ, Lilleyman JS. Impairment of lymphocyte transformation by plasma from patients with advanced Hodgkin’s disease. Cancer 1980; 45: 899–905.PubMedGoogle Scholar
  547. 547.
    Symoens J, Veys E, Mielants W, Pinals R. Adverse reactions to levamisole. Cancer Treat Rep 1978; 62:1721–1730.PubMedGoogle Scholar
  548. 548.
    Taguchi T. Clinical efficacy of lentinan on patients with stomach cancer: Endpoint results of a four-year follow-up survey. Cancer Detect Prev Suppl 1987; 1: 333–349.PubMedGoogle Scholar
  549. 549.
    Takusugi M, Ramseyer A, Takasugi J. Decline of natural non-selective cell-mediated cytotoxicity in patients with tumor progression. Cancer Res 1977; 37: 413–418.Google Scholar
  550. 550.
    Talmadge JE, Lenz BF, Pennington R, et al. Immunomodulatory and therapeutic properties of bestatin in mice. Cancer Res 1986; 46: 9; 4505–4510.PubMedGoogle Scholar
  551. 551.
    Talmadge JE, Lenz B, Schneider M, et al. Immunomodulatory and therapeutic properties of FK-565 in mice. Cancer Immunol Immunother 1989; 28: 93–100.PubMedGoogle Scholar
  552. 552.
    Talpaz M, Medina JE, Patt YZ, et al. The immune restorative effect of cimetidine administration in vivo on the local graft-vs-host reaction of cancer patients. Clin Immunol Immunopathol 1982; 24: 155–160.PubMedGoogle Scholar
  553. 553.
    Tamura K, Shibata Y, Matsuda Y, Ishida N. Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res 1981; 41:3244–3252.PubMedGoogle Scholar
  554. 554.
    Taramelli D, Mazzocchi A, Clemente C, et al. Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytes. Cancer Immunol Immunother 1988; 26: 1,61–66.PubMedGoogle Scholar
  555. 555.
    Tarpley JL, Potvin C, Chretien PB. Prolonged depression of cellular immunity in cured laryngopharyngeal cancer patients treated with radiation therapy. Cancer 1975; 35: 638–644.PubMedGoogle Scholar
  556. 556.
    Tarpley JL, Twomey PL, Catalona WJ, Cretien PB. Suppression of cellular immunity by anesthesia and operation. J Surg Res 1977; 22: 195–201.PubMedGoogle Scholar
  557. 557.
    Tartter PI, Burrows L, Kirshner P. Perioperative blood transfusion adversely affects prognosis after resection in stage I (subset No) non-oat cell lung cancer. J Thorac Cardiovasc Surg 1984; 88: 659–662.PubMedGoogle Scholar
  558. 558.
    Tartter PI, Martinelli G. Lymphocyte subsets, natural killer cytotoxicity, and perioperative blood transfusion for elective colorectal cancer surgery. Cancer Detect Prev (Suppl) 1987; 1:571–576.Google Scholar
  559. 559.
    Tartter PI, Martinelli G, Steinberg B, Barron D. Changes in peripheral T-cell subsets and natural killer cytotoxicity in relation to colorectal cancer surgery. Cancer Detect Prev 1986; 9: 3-4,359–364.PubMedGoogle Scholar
  560. 560.
    Tartter PI, Burrows L, Papatestas AE, et al. Perioperative blood transfusion has prognostic significance for breast cancer. Surgery 1985; 97:225–230.PubMedGoogle Scholar
  561. 561.
    Taylor SA, Gordon MY, Currie GA, Shepherd VB. Irradiation and monocyte function in patients with breast cancer. Int JRad Oncol 1979; 5: 2063–2067.Google Scholar
  562. 562.
    Thatcher N, Palmer MK, Swindell R, Crowther D. Lymphocyte function related to survival curves in patients with metastatic melanoma were evaluated immunologically prior to chemoimmunotherapy. Med Pediatr Oncol 1978; 4: 49–70.Google Scholar
  563. 563.
    Theofilopoulos A, Dixon FJ. The biology and detection of immune complexes. Adv Immunol 1979; 28: 89–220.PubMedGoogle Scholar
  564. 564.
    Thienpont D, Vanparjis OF J, Racymakers AHM, et al. Tetramasole (R8299): A new potent broad spectrum anthelmintic. Nature 1966; 209:1084–1086.PubMedGoogle Scholar
  565. 565.
    Thornes RD, Lynch G, Sheehan MV Cimetidine and coumarin therapy of melanoma. Lancet 1982; 2: 328.PubMedGoogle Scholar
  566. 566.
    Thornes RD, Lynch G. Combination of cimetidine with other drugs for the treatment of cancer. N Engl J Med 1983; 308: 591.Google Scholar
  567. 567.
    Tilden AB, Balch CM. Immune modulatory effects of indomethacin in melanoma patients are not related to prostaglandin E2-mediated suppression. Surgery 1982; 92: 528–532.PubMedGoogle Scholar
  568. 568.
    Ting A, Terasaki PI. Depressed lymphocyte-mediated killing sensitized targets in cancer patients. Cancer Res 1974; 34: 2694–2698.PubMedGoogle Scholar
  569. 569.
    Toge T, Hamamoto S, Itagaki E, et al. Concanavalin-Ainduced and spontaneous suppressor cell activities in peripheral blood lymphocytes and spleen cells from gastric cancer patients. Cancer 1983; 52: 1624–1631.PubMedGoogle Scholar
  570. 570.
    Toivanen A, Granberg I, Nordman E. Lymphocyte subpopulations in patients with breast cancer after postoperative radiotherapy. Cancer 1984; 54: 2919–2923.PubMedGoogle Scholar
  571. 571.
    Tom BH, Macek CM, Subramanian C, et al. In vitro expression of suppressogenic and enhancing activities in human colon cancer cells. J Biol Response Mod 1984; 3: 435–444.PubMedGoogle Scholar
  572. 572.
    Tonnesen H, Knigge U, Bulow S, et al. Effect of cimetidine on survival after gastric cancer. Lancet 1988; 29:2(8618), 990–992.Google Scholar
  573. 573.
    Treurniet-Donker AD, Meischke-de Jongh ML, vanPutten WLJ. Levamisole as adjuvant immunotherapy in breast cancer. Cancer 1987; 59: 1590–1593.PubMedGoogle Scholar
  574. 574.
    Tsang KY, Fudenberg HH, Pan JF, et al. An in vitro study on the effects of isoprinosine on immune responses in cancer patients. Int J Immunopharmacol 1983; 5: 481–490.PubMedGoogle Scholar
  575. 575.
    Tsuyuguchi I, Shiratsuchi H, Fukuoka M. T-lymphocyte subsets in primary lung cancer. Jpn J Clin Oncol 1987; 17: 1,13–17.PubMedGoogle Scholar
  576. 576.
    Uchida A, Kolb R, Micksche M. Generation of suppressor cells for natural killer activity in cancer patients after surgery. J Natl Cancer Inst 1982; 68: 735–741.PubMedGoogle Scholar
  577. 577.
    Uchida A, Mickskche M. Generation of suppressor cells f or natural killer (NK) activity in cancer patients after surgery. Cancer Immunol Immunother 1981; 10:203–210.Google Scholar
  578. 578.
    Uchida A, Hoshino T. Clinical studies on well-mediated immunity in patients with malignant disease. I. Effects of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer 1980; 45:476–483.PubMedGoogle Scholar
  579. 579.
    Umeda T, Yokoyama H, Kobayashi K, et al. Subsets of Tlymphocytes of patients with malignancies of the urogenital tract. Cell Mol Biol 1979; 25: 95–99.Google Scholar
  580. 580.
    Unger SW, Bernhard MI, Pace RC, Wanego HJ. Monocyte dysfunction in human cancer. Cancer 1983; 51: 669–674.PubMedGoogle Scholar
  581. 581.
    Uracz W, Mytar B, Zembala M, et al. Activated monocytes in gastric cancer patients. II. Suppressor and cytostatic activity in vitro. J Cancer Res Clin Oncol 1982; 104: 307–313.PubMedGoogle Scholar
  582. 582.
    VanRijswijk REN, DeMeijerA, Bob Sybesma JPH, Kater L. Five-year survival in Hodgkin’s disease. The prospective value of immune status at diagnosis. Cancer 1986; 57: 1489–1496.PubMedGoogle Scholar
  583. 583.
    Van-Stolen K, Wiernick PH, Schiffer CA, Schimpff SC. Evaluation of levamisole as an adjuvant to chemotherapy for treatment of ANLL. Cancer 1983; 51: 1576–1580.Google Scholar
  584. 584.
    Vanhaelen CP J, Fisher RI. Increased sensitivity of T-cells to regulation by normal suppressor cells persists in longterm survivors with Hodgkin’s disease. Am J Med 1982; 72: 385–390.PubMedGoogle Scholar
  585. 585.
    Vaudaux P, Kiefer B, Forni M, et al. Adriamycin impairs phagocytic function and induces morphologic alterations in human neutrophils. Cancer 1984; 59:400–410.Google Scholar
  586. 586.
    Venkataraman M, Rao DS, Levin RD, Westerman MP. Suppression of B-lymphocyte function by T-lymphocytes in patients with advanced lung cancer. J Natl Cancer Inst 1985; 74: 37–41.PubMedGoogle Scholar
  587. 587.
    Verhaegen H, DeCree J, DeCock W, et al. Levamisole therapy in patients with colorectal cancer. In: Terry WDRosenberg SA, eds. Immunotherapy of human cancer. New York: Elsevier/North-Holland, 1982: 225–229.Google Scholar
  588. 588.
    Vinzenz K, Matejka M, Watzek G, et al. Modulation of NK activity in regional lymph nodes by preoperative immunotherapy with OK-432 in patients with cancer of the oral cavity. Cancer Detect Prev Suppl 1987; 1: 463–475.PubMedGoogle Scholar
  589. 589.
    VonRoenn J, Harris JE, Braun DP Suppressor cell function in solid-tumor cancer patients. J Clin Oncol 1987; 5: 1; 150–159.Google Scholar
  590. 590.
    Voogt PJ, van de Velde CJH, Brand A, et al. Perioperative blood transfusion and cancer prognosis: Different effects of blood transfusion on prognosis of colon and breast cancer patients. Cancer 1987; 59: 836–843.PubMedGoogle Scholar
  591. 591.
    Vose BM, Vanky F, Argrov S, Klein E. Natural cytotoxicity in man: Activity of lymph node and tumorinfiltrating lymphocytes and regional lymphocytes. Eur J Immunol 1977; 7: 753–757.Google Scholar
  592. 592.
    Wagner DK, Kiwanuka J, Edwards BK, et al. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J Clin Oncol 1987; 5: 8,1262–1274.PubMedGoogle Scholar
  593. 593.
    Wagner V, Janku O, Wagnerora M, et al. The production of complete and incomplete antibodies in patients with neoplastic disease. Neoplasma 1972; 19: 75–87.PubMedGoogle Scholar
  594. 594.
    Wakasugi H, Kasahara T, Minato N, et al. In vivo potentiation of human natural killer cell activity by a streptococcal preparation: interferon and interleukin-2 participation in the stimulation with OK-432. J Natl Cancer Inst 1982; 69: 807–812.PubMedGoogle Scholar
  595. 595.
    Waller CA, Gill BG, Machennon IC. Enhancement of lymphocyte-mediated cytotoxicity after tumor resection in patients with colorectal cancer. J Natl Cancer Inst 1980; 65:223–230.PubMedGoogle Scholar
  596. 596.
    Walter RJ, Danielson JR. Defective monocyte chemotaxis in patients with epidermoid tumors of the head and neck. Arch Otolaryngol 1985; 11: 530–540.Google Scholar
  597. 597.
    Wanebo HJ, Rao B, Miyazawa N, et al. Immune reactivity in primary carcinoma of the lung and its relation to prognosis. J Thorac Cardiovasc Surg 1976; 72: 339–347.PubMedGoogle Scholar
  598. 598.
    Wanebo HJ, Pace R, Hargett S, et al. Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients. Cancer 1980; 57: 656–662.Google Scholar
  599. 599.
    Wanebo HJ, Jun M, Strong E, Oettgen HF. T-cell deficiency in patients with squamous-cell cancer of head and neck. Am J Surg 1975; 130:445–451.PubMedGoogle Scholar
  600. 600.
    Wanego HJ, Rao B, Attiyeh F, et al. Immune reactivity in patients with colorectal cancer: assessment of biological risk by immunoparameters. Cancer 1980; 45: 1254–1263.Google Scholar
  601. 601.
    Wanebo HJ, Hilal EY, Strong EW, et al. Adjuvant trial of levamisole in patients with squamous cancer of the head and neck: a preliminary report. Cancer Res 1978; 68: 324–333.Google Scholar
  602. 602.
    Wanebo HJ. Observations on the effects of adjuvant radiation on immune tests of patients with colorectal cancer and head and neck cancer. In: Dubois JBSerrou BRosenfeld C, eds. Immunopharmacologic effects of radiation therapy. New York: Raven Press, 1980:241–252.Google Scholar
  603. 603.
    Wanego HJ, Riley T, Katz D, et al. Indomethacin-sensitive suppressor-cell activity in head and neck cancer patients. Cancer 1988; 61:462–474.Google Scholar
  604. 604.
    Wara WM, Phillips TL, Wara DW, et al. Immunosuppression following radiation therapy for carcinoma of the nasopharynx. Am J Roentgenol Radium Ther Nucl Med 1975; 123:482–485.PubMedGoogle Scholar
  605. 605.
    Wara WM, Wara DW, Philips TL, Amman AJ. Elevated IgA in cancer of the nasopharynx. Cancer 1975; 35:1313–1315.PubMedGoogle Scholar
  606. 606.
    Wara WM, Neely MH, Amman AJ, Wara DW. Biological modification of immunologic parameters in head and neck cancer patients with thymosin fraction V In: Goldstein ALChirigos MA, eds. Lymphokines and thymic hormones: their potential utilization in cancer therapeutics. New York: Raven Press, 1981: 257–262.Google Scholar
  607. 607.
    Warren RP, McCall CA, Urban RW. Augmentation of natural killer cell activity by ImuVert: a biological response modifier derived from Serratia marcescens. Mol Biother 1989; 1:; 3,145–151.PubMedGoogle Scholar
  608. 608.
    Wasserman J, Wallgren A, Blomgren H, et al. Prognostic relevance of post-irradiation lymphocyte reactivity in breast cancer patients. Cancer 1986; 58: 348–351.PubMedGoogle Scholar
  609. 609.
    Wasserman J, Blomgren H, Petrini B, et al. Effect of radiation therapy and in vitro x-ray exposure on lymphocyte subpopulations and their functions. Am J Clin Oncol 1982; 5: 195–208.PubMedGoogle Scholar
  610. 610.
    Watanabe Y, Takashi I. Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432. Cancer 1984; 53:248–253.PubMedGoogle Scholar
  611. 611.
    Webster DJ, Whitehead RH, Richardson G, Hughes LE. Levamisole: A double-blind immunological study. Anticancer Res 1982; 2: 29–32.PubMedGoogle Scholar
  612. 612.
    Weiden PL, Bean MA, Schultz P. Perioperative blood transfusion does not increase the risk of colorectal cancer recurrence. Cancer 1987; 60: 870–874.PubMedGoogle Scholar
  613. 613.
    Wells SA Jr, Burdick JF, Christiansen C, et al. Demonstration of tumor-associated delayed cutaneous hypersensitivity reactions in lung cancer patients and in patients with carcinoma of the cervix. Natl Cancer Inst Monogr 1973; 37: 197–203.PubMedGoogle Scholar
  614. 614.
    Wells SA Jr, Burdick JF, Christiansen C, et al. Demonstration of tumor-associated delayed cutaneous hypersensitivity reactions in lung cancer patients and in patients with carcinoma of t he cervix. Natl Cancer Inst Monogr 1973; 37: 197–203.PubMedGoogle Scholar
  615. 615.
    Wells SA Jr, Burdick JF, Joseph WL, et al. Delayed cutaneous hypersensitivity reactions to tumor cell antigens and to nonspecific antigens. J Thorac Cardiovasc Surg 1973; 66: 557–562.PubMedGoogle Scholar
  616. 616.
    Weppelmann B, Monkemeir D. The influence of prostaglandin antagonists on radiation therapy of carcinoma of the cervix. Gynecol Oncol 1984; 17: 196–199.PubMedGoogle Scholar
  617. 617.
    Wesse J, Oldham RK, Tormey DC, et al. Immunologic monitoring in carcinoma of the breast. Surg Gynecol Obstet 1977; 145:209–218.Google Scholar
  618. 618.
    Wesselius LJ, Wheaton DL, Manahan-Wahl LJ, et al. Lymphocyte subsets in lung cancer. Chest 1987; 91: 5; 725–729.PubMedGoogle Scholar
  619. 619.
    White JE, Chen T, Reed R, et al. Limited squamous-cell carcinoma of the lung: a Southwest Oncology Group randomized study of radiation with or without doxorubicin and with or without levamisole immunotherapy. Cancer Treat Rep 1982; 66: 113–120.Google Scholar
  620. 620.
    Whitehead RH, Thatcher J, Teasdale C, et al. T- and Blymphocytes in breast cancer: stage relationship and abrogation of T-lymphocyte depression by enzyme treatment in vitro. Lancet 1976; 1: 330–333.PubMedGoogle Scholar
  621. 621.
    Wilkins SA Jr, Olkowskii ZL. Immunocompetence of cancer patients treated with levamisole. Cancer 1977; 39: 487–493.PubMedGoogle Scholar
  622. 622.
    Windle R, Bell PR, Shaw D. Five-year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 1987; 74: 7, 569–572.PubMedGoogle Scholar
  623. 623.
    Windle R, Wood RFM, Bell PRF. The effect of levamisole on post-operative immunosuppression. Br J Surg 1979; 66: 507–509.PubMedGoogle Scholar
  624. 624.
    Wleklik MS, Luczak M, Najjajr VA. Tuftsin-induced tumor necrosis activity. Mol Cell Biochem 1987; 75: 2, 169–174.PubMedGoogle Scholar
  625. 625.
    Wolf GT, Lovett EJ III, Peterson KA, et al. Lymphokine production and lymphocyte subpopulations in patients with head and neck squamous carcinoma. Arch Otolaryngol 1984; 110: 731–735.PubMedGoogle Scholar
  626. 626.
    Wolf GT, Amendola BE, Diaz R, et al. Definite vs. adjuvant radiotherapy. Comparative effects on lymphocyte subpopulations in patients with head and neck squamous carcinoma. Arch Otolaryngol 1985; 111: 716–726.PubMedGoogle Scholar
  627. 627.
    Wybran J, Govaerts P Levamisole and human lymphocyte surface markers. Clin Exp Immunol 1977; 27: 319–321.PubMedGoogle Scholar
  628. 628.
    Wybran J, Serrou B, Belpomme D, et al. Immunomodulating of T-cell and NK function by NPT-15392 in cancer patients. A cooperative study by the tumor immunology group. In: Serrou BRosenfeld CDaniels JCSaunders JP, eds. Current concepts in human immunology and cancer immunomodulation. Amsterdam: Elsevier Biomedical, 1982:471–478.Google Scholar
  629. 629.
    Yokoyama H, Umeda T, Kobayashi K, et al. Restoration of E-rosette formation by bestatin in patients with bladder cancer. C Cancer Res Clin Oncol 1980; 98: 195–201.Google Scholar
  630. 630.
    Young RC, Corder MP, Haynes HA, DeVita VT. Delayed hypersensitivity in Hodgkin’s disease. Am J Med 1972; 52: 63–72.PubMedGoogle Scholar
  631. 631.
    Zabbe C, DeWitte JD, Lozach P, et al. Predictive value of T-cell subset derangements in lung cancer. Med Oncol Tumor Pharmacother 1986; 3: 2; 83–85.PubMedGoogle Scholar
  632. 632.
    Zacharski LR, Linman JW. Lymphocytopenia: its causes and significance. Mayo Clin Proc 1971; 46: 168–173.PubMedGoogle Scholar
  633. 633.
    Zamkoff KW, Reeves WG, Paolozzi FP, et al. Impaired interleukin regulation of the phytohemagglutinin response in Hodgkin’s disease. Clin Immunol Immunopathol 1985; 35: 111–124.PubMedGoogle Scholar
  634. 634.
    Zamkoff KW, Reeves WQ, Paolozzi FP, et al. Impaired interleukin regulation of the phytohemagglutinin response in Hodgkin’s disease. Clin Immunol Immunopathol 1985; 35: 111.PubMedGoogle Scholar
  635. 635.
    Zanker KS, Blumel G, Lange J, et al. Coumarin in malignant melanoma patients: an experimental and clinical study. Drug Exp Clin Res 1984; 10: 767–774.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Robert K. Oldham
    • 1
    • 2
  1. 1.Biological Therapy Institute FoundationFranklinUSA
  2. 2.University of MissouriColumbiaUSA

Personalised recommendations